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A new class of soft hydrogel-based macroporous sponge made of cellulose derivative 
has been synthesized and investigated for several hepatocyte-based applications.  
Firstly, we have synthesized and fabricated a galactosylated macroporous cellulosic 
hydrogel sponge as a platform to culture primary rat hepatocytes as 3D spheroids for 
in vitro drug safety testing applications.  The soft macroporous cellulosic sponge with 
conjugated galactose facilitates the formation of hepatocyte spheroids by presenting 
both the mechanical cues (via matrix rigidity) and chemical cues for the hepatocytes 
to reorganize into 3D spheroids within 7 hours post-seeding. The constrained 
hepatocyte spheroids maintain cell viability, cell polarity markers, and 3D cell 
morphology. These translate into maintained hepatocyte-specific functions and 
expression of drug metabolic enzymes and drug transporters. Furthermore, hepatocyte 
spheroids grown in the sponge show inducibility of various drug metabolizing 
enzymes including CYP1A2, CYP2B2 and CYP3A1, with higher mean basal drug 
metabolizing expression. The sponge also has comparable or lower drug absorbency 
compared to other cell culture scaffolds.  
Secondly, we have elucidated the usefulness of our galactosylated cellulosic sponge 
for primary human hepatocyte and Huh 7.5 cell 3D culture as spheroids for multi-well 
HCV entry and inhibition study. Human hepatocyte and Huh 7.5 spheroids are formed 
in the sponge within 24 hours post-seeding and constrained in the sponge 
macroporosity for prolonged culture. The size of the spheroids lies within mass 
transfer barrier-free range. Spheroids viability is well maintained up to 5 and 2 weeks 
for human hepatocyte and Huh 7.5, respectively. The compact spheroids morphology 
is observed at least up to 2 weeks of culture. Compact spheroids morphology 
xiv 
 
correlates well with gene expression showing minimal dedifferentiation of human 
hepatocyte spheroids and upregulation of mature hepatocyte genes in Huh 7.5 
spheroids. Both types of spheroids express liver polarity markers and HCV entry 
markers. When these spheroids are inoculated with HCVpp, an available in vitro 
model to study HCV entry, ~80% of the spheroids are infected with HCVpp 
distributed throughout whole spheroids region. Human hepatocyte spheroids have 
shown the ability to be infected at prolonged culture indicating the maintenance of 
HCV entry markers. By co-incubating both types of spheroids with HCVpp and CD81 
antibody, HCVpp entry is inhibited at dose-dependent manner.  
And lastly, we have tuned the property of the cellulosic sponge into a cleavable 
hydrogel sponge, with conjugated galactose as a platform to culture primary rat 
hepatocytes as 3D spheroids with the ability to retrieve the spheroids at physiological 
condition. Hepatocyte spheroids retrieval is performed through rapid non-cytotoxic 
sponge cleavage. The soft macroporous structure of cleavable cellulosic sponge 
conjugated with galactose facilitates the formation of hepatocyte spheroids by 
presenting both the mechanical cues (via matrix rigidity) and chemical cues for the 
hepatocytes to reorganize into 3D spheroids within 24 hours post-seeding. The 
constrained hepatocyte spheroids maintain cell viability for at least a week of culture. 
Upon spheroids retrieval through sponge cleavage, polarized hepatocyte phenotypes 
are well maintained; drug metabolizing enzymes (CYP1A2, CYP2B2 and CYP3A2), 
polarity marker (cortical F-actin), tight cell-cell adhesion, apical hepatocyte domain 
marker (MRP2), biliary excretory function, spheroid compact morphology and cell 
viability. The living retrieved spheroids are replatable on both collagen coated and 
poly-L-lysine coated dishes for further use. 
 xv 
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The recent increasingly explored 3D cell culture technology has made various 
efforts towards presenting complexity to the cultured cells in vitro for various 
biomedical and pharmaceutical applications ranging from bio-artificial assisted 
devices to drug and antiviral screening platforms [1-4]. This new concept of culturing 
cells in 3 dimensions was initiated by various revealed facts that cells behaved 
differently compared to their native niche when they were cultured on conventional 
flat tissue culture flasks, known as 2D culture [5]. 2D culture is also unable to present 
the complexity of in vivo tissue modality in vitro thus could not correlate between the 
real tissue physiological microenvironment and cultured cells [5]. The possibility of 
culturing cells in 3D microenvironment mimicking the microenvironments in the 
native organ could enhance various biological investigation responses which possibly 
cannot be performed in the organ directly due to ethical issues and source scarcity. 
Culturing cells in the 3D culture and having close correlation with the studied organ 
could then minimize the use of expensive and labor extensive animal studies.  
The design of the existing 3D cell culture technology was inspired by the 
architecture of the cells orchestration in vivo in the organ and their replica was built 
using bottom top approach towards tissue miniature. By combining various scientific 
backgrounds such as cell biology, materials science and bio-imaging technique, 
various kinds of 3D cell culture technology can replicate the tissue complexities in 
vitro, known as engineered tissue. This technology also ranges from microscale into 
macroscales for different applications in the current bioengineering demands.  
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During development of 3D cell culture technology, thing to consider is a way to 
mimic how cells in vivo interact with neighboring cells and with their own native 
matrices, known as cell-cell and cell-matrix interaction, respectively. Efforts to create 
3D culture by looking at these factors hopefully can restore cell functionalities in vitro 
better than what people conventionally have done for decades, by just simply plating 
the cells on a flat tissue culture flask. 
A different way to culture cells in 3D is by using a scaffold. The classical 
principle of synthetic polymeric scaffold usefulness in 3D cell culture technology and 
tissue engineering is to serve as temporary conducive template for cells to attach and 
maintain the functions prior to implantation [6, 7]. Therefore scaffold properties play 
important role in controlling 3D cellular microenvironments. By closely mimicking in 
vivo 3D cellular microenvironment cellular functions can be preserved prior to 
implantation [8]. Many factors in the scaffold are regulating cell survival, 
proliferation, differentiation and functions such as spatially and temporally controlled 
milieu of biochemical and topographical cues which includes interconnectivity of 
sponge porosity, mechanical stiffness and required cell ligand presentation [9]. 
Examples of classically studied scaffolds in the past are polylactic acid (PLA), 
polyglycolic acid (PGA), polycaprolactone or their blends [10]. However, these 
examples limit the application for soft tissue cultures due to relatively hydrophobic 
scaffold surface property, stiff mechanical stiffness, and even fabrication step which 
involves toxic organic solvents [11].  
In this project, we would like to propose a novel hydrogel scaffold sponge made 
of cellulose derivative as the basic material for multi-well format 3D culture. The 
porous structure of the sponge was created by cellulose colloidal nanoparticles, which 
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are temperature responsive substances [12, 13]. The primary concept of making 
porous cellulose hydrogel from cellulose nanoparticle networks was introduced in 
year 2000 by Zhibing et al. and the early development of our cellulosic sponge for 3D 
cell culture has been elucidated by Yue et al. in 2010 [14, 15]. The advantages of 
making hydrogel from nanoparticles networks are it has two levels structural 
hierarchies’ e.g. primary network of polymer chain and secondary network of 
cellulose nanoparticles. In comparison with other porous gels, the nanoparticle 
network hydrogel has the advantages of high uniformity and easily tunable mesh sizes. 
For example, pore size in a nanoparticle network can be well controlled by varying 
either nanoparticle size (molecular weight of the cellulose used) or the average 
number of nearest neighbors (polymer concentration in solvent) [14].   
We propose by combining the advantages of hydrogel as soft tissue matrix and 
sponge macroporosity, we can present proper spatiotemporal cues for soft-tissue 
cultures.  Found to be abundant in bacteria and plant fibers, cellulose has been studied 
extensively as drug carrier in drug delivery research [16-19], bioadhesive cellulose 
gels as vascosurgical devices, investigations in bone tissue engineering, cartilage 
tissue engineering and tissue engineering in post-injury brain and for connective 
tissue formation [20]. Cellulose derivative we used in the sponge synthesis and 
fabrication is hydroxypropyl cellulose (HPC) which is more water soluble as 
compared to the original native cellulose material.  In addition to its high water 
solubility, HPC has also been proven to be biocompatible with an example of HPC-
based FDA-approved commercial artificial tears material (Lacrisert) [21-23]. Thus the 
sponge materials construction is based on water environment hence named hydrogel 
sponge.   
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Three-dimensional construct formed in the porous sponge we are interested to 
observe is multi cellular aggregates, or called hepatocyte spheroids. Hepatocyte 
spheroids are three-dimensional, multi-cellular aggregates that exhibit high degree of 
cell-cell contacts. These spheroids sustain viability for extended culture periods and 
maintain higher level of liver-specific functions including albumin secretion, 
ureagenesis and cytochrome P450 activity, as compared to hepatocytes cultured as 2D 
monolayer [24]. Proven to be able to maintain polarity gradually and functionally 
resemble bile canaliculi, hepatocyte spheroids also possess tubular structure encircled 
with actin, similar to bile canaliculi observed in vivo [25].  
3D spheroid culture has been extensively used in vitro for various cell types e.g. 
cancer, primary cells and stem cells [5, 25-28]. The extensive cell-cell interaction in 
the spheroid is analog to in vivo environment in promoting partial function 
maintenance of original tissue. These spheroids can be maintained without 
vascularization when the size of spheroid diameter is within diffusible dimension (less 
than 200 µm) to allow sufficient nutrients and oxygen penetration [29]. And most 
importantly, the hepatocyte spheroid can be a good and simple model in drug 
metabolism and hepatitis viral infection study. 
 
Thesis hypothesis, project objectives and specific aims of the thesis 
The general thesis hypothesis is macroporous cellulosic sponge can provide 
optimum physical and chemical cues for formation of functional and constraint 
hepatocyte spheroids for drug testing and antiviral screening applications. Final 
aim of this study is to have a robust hydrogel sponge scaffold with improved 
properties in terms of materials properties and cellular spatiotemporal cues as in vitro 
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drug safety testing and anti-viral screening platform. The basic material we are using 
is hydroxypropyl cellulose with interesting hydrogel properties. Being hydrogel-based 
cellulosic sponge, the hydrophilicity and stiffness properties is tunable for soft tissue 
cultures [30]. Not forget to mention, our cellulose sponge is also easily functionalized 
with ligands or other chemical modifiers thus provides versatility for further 
applications i.e for synthesizing a cleavable sponge.   
This project focused on the development of multi-well cellulosic sponge for 3D 
hepatocyte culture and utilization of the sponge as in vitro cell drug safety testing 
platform and anti-viral screening using primary and human liver tumor-derived cells 
e.g. primary rat and human hepatocyte as well as human liver cell line (Huh 7.5 cell). 
There are several methods researchers have performed in the past to form 3D 
cellular spheroids such as hanging drop technique, rotary culture of cell suspension on 
positive substrate (Primaria dish), cells entrapment in 3D hydrogel matrices,  
polymeric nanofibers scaffolds and cellular linker [24, 26, 31-33]. However, the 
process for Primaria dish culture can be tedious, after spheroids are formed they still 
need to be embedded in matrigel to serve as supporting substrate thus spheroid can be 
manipulated for further assay. Whereas nanofiber scaffolds have limitation for 
fabrication in larger scale due to its complex fabrication. In addition, higher surface 
per volume ratio of nanofiber may increase drug absorption.  
Hence we have been thinking to propose a novel thin hydrogel sponge which 
would be able to form hepatocyte spheroids rapidly in response to the sponge 
mechanical stiffness, porosity and proper ligand presentation (galactose for 
hepatocyte), easy cell seeding procedure, low drug absorption as well as versatile 
manipulation of spheroids cultured in the sponge. Hepatocyte spheroids we refer here 
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are constrained and tethered hepatocyte spheroids in the macroporous network of the 
cellulosic sponge, rather than encapsulated in the sponge. Developing this constrained 
hepatocyte spheroid in the macroporous sponge is an improvement of previous work 
on galactose-conjugated polyethylene terephthalate membrane [34]. This membrane 
could form hepatocyte spheroids but at slow speed i.e. 3 days post-seeding and 
showed drawback in prolonged culture i.e. the inability of the membrane to anchor 
compact spheroids on the surface more than one week.  In addition, this membrane 
could not guarantee to form a stable constrained cryopreserved primary human 
hepatocyte spheroids for prolonged culture, due to 5 folds less ASGPR receptors in 
human hepatocyte compared to rat hepatocytes [35].  
Towards realization use of our in house cellulosic sponge 3D culture platform, 
which is inspired by the hepatocyte orchestration in liver lobe, three specific aims of 
this thesis are divided as follows. 
 
Specific Aim 1 
To develop galactosylated cellulosic sponge for 3D hepatocyte culture and drug safety 
testing 
Hypothesis 
Presentation of galactose ligands in macroporous cellulosic sponge can help 
inducing rapid and functional hepatocyte spheroids and subsequently constrain 





1) Optimize the synthesis and fabrication of galactosylated cellulosic sponge with 
the soft hydrogel characteristics 
2) Prove that cultured primary rat hepatocyte could rapidly reorganize to form 
hepatocyte spheroids and maintain the function for one week culture period 
3) Move towards the application of the hepatocyte spheroid cultured in 
galactosylated cellulosic sponge for drug induction study 
 
Specific Aim 2 
To use the galactosylated cellulosic sponge as multi-well platform to study hepatitis C 
virus infection 
Hypothesis 
Constraint hepatocyte spheroids in the well-plate based macroporous cellulosic 
sponge have enhanced hepatocyte polarity and localization of hepatitis C virus 
entry receptors thus useful for antiviral screening 
Experimental designs 
1) Observe, assess and prove the rapid formation of primary human hepatocyte and 
Huh 7.5 spheroids in the galactosylated cellulosic sponge,  
2) Characterize the hepatocyte polarity markers, requirements for hepatitis C virus 
infection study, over prolonged culture  
8	  
	  
3) Investigate the hepatitis C virus entry markers in the spheroids and prove their 
existence 
4) Study and show the hepatitis C viral entry and inhibition in the cultured 
hepatocyte spheroids 
 
Specific Aim 3 
To synthesize and fabricate the cleavable cellulosic sponge for 3D hepatocyte culture 
and spheroids retrieval 
Hypothesis 
Reducible disulfide bonds insertion into the side chain groups of hydroxypropyl 
cellulose makes cellulosic sponge rapidly cleavable in physiological reduction 
environment 
Experimental designs 
1) Optimize the synthesis and fabrication steps of cleavable cellulosic sponge and 
investigate the cleavage rate of this new generation of the sponge in 
physiological and non-toxic reduction environment 
2) Establish the platform to culture primary rat hepatocyte as spheroids and show 
rapid formation of these spheroids 
3) Study and prove the ability to retrieve the cultured hepatocyte spheroids 
physiologically by cleaving the sponge  
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4) Elucidate the effect of cleaving process in the retrieved hepatocyte spheroids 
and prove the harmless effect of the reductant addition 
This thesis elucidates the general introduction of the study as well as thesis 
specific aims in chapter 1. Chapter 2 covers the background theory and significance of 
the project we have been working. Chapter 3 explains the development of 
galactosylated cellulosic sponge to culture primary rat hepatocyte as spheroids for 
multi-well drug safety testing platform. Chapter 4 discusses the application of 
galactosylated cellulosic sponge to culture primary human hepatocyte and Huh 7.5 
spheroids as a platform to study hepatitis C infection. Chapter 5 includes the further 
development of new generation of cellulosic sponge towards cleavable sponge for 
easy and rapid retrieval of hepatocyte spheroids cultured in the sponge. And to 
summarize this thesis, conclusion and recommendations for future works are covered 













BACKGROUND AND SIGNIFICANCE 
 
2.1 Liver physiology 
Liver is a known organ that can rejuvenate by itself up to 80% mass loss in case 
of any injury [36]. It is body largest internal organ, which has four lobes, weighing 
about 1.4-1.6 kilogram and possesses complex functions in regulating body 
homeostasis [37]. In the body, liver serves numerous functions such as: a) synthesize 
proteins such as albumin, low density lipoprotein and coagulation factor, b) glycogen 
storage from glucose and converts it back for the needed energy, c) metabolize fatty 
acids, amino acids and cholesterol, d) produce biles to break down fats into smaller 
components and the most important function that is covered in this thesis is e) 
detoxification and elimination of toxic substances i.e. drugs by its cytochrome P450 
enzymes to be more easily excreted substances [38] . 
There are 4 major different cell types present in the liver such as hepatocytes, 
sinusoidal endothelial cells, Kupffer cells, and stellate cells [39] . Hepatocytes which 
count of ~80% liver cell mass play the most significant role in doing the job in liver 
metabolic, secretory and detoxifying capability [40]. Therefore in most liver tissue 
engineering platforms, primary hepatocyte is considered to be the main cell used in 
the model [41].   
As shown in figure 1, hepatocytes are orchestrated in the liver lobe in a 
complex manner; the cells are aligned in a regular manner where cell-cell and cell-
matrix play important roles in regulating cellular functions. The channels formed 
between adjacent hepatocytes called bile canaliculi, a thin tube-like structure which 
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collects bile secreted by hepatocytes. In the extended area, bile canaliculi merge and form 
bile ductules, which finally perpetuate as bile duct. In between each row of hepatocytes, 




Figure 1. Anatomy of human liver and its biliary tracts (adapted from [37]) 
 
In this sinusoid, there are Kupffer cells which have similar functions like 
macrophages: to get rid of amino acids, nutrients, sugar, old red blood cells, bacteria 
and other debris from the blood. The functions of sinusoid are to destroy old red blood 
cells, bacteria and other foreign particles from the blood and to detoxify toxins and 
harmful substances. Other cells beside these cells are also present such as biliary 
epithelial cells, hepatocyte precursor cells (or called small hepatocyte) and fibroblasts 
which also perform metabolic capability. In estimation, liver is flown with 1.5 L of 
blood per minute, 75% of this blood comes through portal vein and the rest is oxygen-
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rich blood carried by hepatic artery. This thus indicates liver as one of the most 
vascularised organ in the body [42].  
The hepatocytes arrangement in the liver lobe also depicts the importance of 
this structure for liver functions. The cell substratum, cell-cell interaction as well as 
other cues like shear stress and or chemical cues have significant effects into how well 
the cells function and do their duty [43]. Various efforts to regenerate healthy and 
well function hepatocyte in vitro are inspired by these phenomena.  
 
2.2 In vitro liver regeneration 
Liver transplantation is a known treatment in resolving end-stage liver disease, 
however donor organ shortage remains a serious problem [44]. Bunch of patients are 
dying while seeking for a transplant and those with chronic disease often deteriorate 
resulting in lower chance of survival after transplantation. Thus a device that can 
support liver function until liver from a donor became available or the patient’s own 
liver recovered is an aim. Extensive researches to regenerate artificial liver 
microtissues have been fostered since few decades back, known as Extracorporeal 
Bioartificial Liver Devices or Bioartificial Liver Assisted Devices (BLAD) [45]. This 
bioartificial liver is an extracorporeal device filled with living primary hepatocytes for 
temporary support of liver functions. Most of the other available liver assisted support 
systems could get rid of toxins normally metabolized by liver through dialysis, 
charcoal hemoperfusion or exchange transfusion [46-48]. However still none of these 
systems can have complete complex functions performed by a normal and healthy 
liver.  
It is known to be a major challenge to maintain the differentiated phenotypic 
characteristics and functions of hepatocytes in the culture more than a week since it is 
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difficult to mimic the proper microenvironment for hepatocytes to proliferate and 
function [49]. These adhesion-specific cells require intricate interplay of various 
important factors to maintain proper biological functions failing which hepatocyte 
will trans-differentiate into fibroblast-like cells. Hepatocytes as the functional cell 
source in BLAD must be maintained by cultivating the cells in 3D structure, such as 
sandwiching them between two collagen gel layers [50]. In this configuration, 
hepatocytes can secrete functional markers at physiological levels. Hepatocytes must 
also be attached to polymer substrata to maintain their differentiated functions and 
viability. Hepatocytes cultured on appropriate polymers can form tissue resembling 
those observed in organ and shown evidence of bile ducts formation and bilirubin 
removal [51]. By culturing hepatocytes within artificial scaffolds, they can be cultured 
in vitro then transplanted in vivo which can be performed in the diseased liver, but 
still the trans-differentiation of these cells remains a major challenge [52]. From this 
observation, plating hepatocytes on a carefully designed and appropriate substratum 
points out a very important factor in maintaining differentiated functions correlated 
with cell-matrix interaction. 
 
2.3 Scaffolds for liver tissue engineering 
Tissue engineering scientists have made extensive efforts to develop variety of 
scaffolding materials to regenerate scalable tissues such as nerve, skins, bone and 
blood vessels [53]. Scaffold is a temporary construct that mimics the native 
extracellular matrix (ECM) of the tissues to provide structural integrity of tissues and 
facilitate cells to adhere, proliferate and migrate [54]. It provides suitable 
microenvironments to the cells for maintaining proper functions [55]. Therefore it is 
important to create scaffolds that mimic the ECM properties of the native tissues. The 
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successfulness of these ECM-mimicry scaffolds developments lies in the matrix 
design to support cell adhesion, proliferation, maturation and differentiation. In 
specific for liver tissue engineering, the scaffolds need to be accommodating cell 
adhesion with permissive microenvironment and surface chemistry, three dimensional 
features to promote cell-cell contact and desirable porosity to maintain diffusion of 
nutrients and gas exchange. Mechanically soft scaffolds are desirable to prevent cells 
spreading which could induce dedifferentiation.  
Approaches to establish proper cell-matrix interaction in anchorage-dependent 
cells i.e. hepatocyte cultures have been developed to regenerate tissues by attaching 
isolated cells to scaffolding biomaterials that serve as guiding structures for initial 
tissue development. Other approaches such as culturing hepatocyte in suspension, 
liver microsomes or culturing precision liver slices could not exhibit long term 
stability since they are unable to mimic the in vivo liver microenvironment completely 
[32, 56, 57]. Ideal scaffolds should be biocompatible, non-toxic and manufacturable 
[58]. Different forms of scaffolds such as nanofibers, membranes and hydrogels that 
attempted to mimic liver extracellular matrices have been developed to sustain liver 
metabolic functions for successful liver tissue regeneration [24, 59, 60]. Many 
methods involved in the fabrication steps of the scaffold with desirable properties for 
regenerating liver tissues such as phase separation, particular leaching, freeze-thaw 
and electrospinning [24, 61-63]. 
Important factors in the scaffold design and fabrication that have to be strictly 
controlled are a) pore size and porosity to maintain proper diffusion of nutrients and 
gas exchange for cellular growth and b) scaffold surface chemistry to present proper 
cues to the cells grown in the region. When the pore size of the scaffolds is larger than 
500 µm, cells cannot migrate anymore to reorganize as they do not recognize the 
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surface anymore. Pore size with high interconnectivity should ideally be in the range 
of 50 to 150 µm for hepatocyte culture [64]. Within this dimension, hepatocytes cell-
cell contact would be enhanced to maintain their differentiated phenotypes when 
compared to two dimensional systems. Hepatocytes when cultured on 2D collagen 
monolayer tend to dedifferentiate rapidly and lost their liver specific functions [65].  
The surface chemisty of the scaffold material will also influence cell adhesion, 
proliferation and functions. When hepatocytes were cultured on an Arginine-Glycine-
Aspartate (RGD) modified polyethylene glycol gel and type 1 collagen modified 
polysulfonate sponges, long term enhancement of liver differentiated functions have 
been observed but not on the unmodified respective substrates [61, 66]. Therefore, 
incorporation of cell-adhesion specific ligands on the scaffold surface is important to 
promote cell-matrix interaction. 
Scaffold raw materials can be natural materials such as extracellular 
components (collagen, fibronectin, fibrin, laminin, matrigel) or decellularized liver 
matrices [67]. However, these natural materials scaffold are not cost-effective, impose 
batch-to-batch variation, may induce immunogenic reactions as well as in particular 
for matrigel, the exact composition of its constituent is still unknown thus rendering 
its irreproducibility [68, 69]. On the other hand synthetic materials are advantageous 
in their chemistry and materials properties to be well controlled and tunable [70]. 
Scaffold-based tissue engineering in majority has utilized synthetic polymers e.g. poly 
(glycolic acid) (PGA), poly (lactic acid) (PLA), or poly (hydroxyl alkanoate) (PHA) 
[71]. These polymer scaffolds are designed to guide cell organization and growth 
allowing proper diffusion of nutrient to the cells. However, the use of these polymers 
for liver tissue engineering applications is limited with the lack of cell recognition 
motif and mechanical stiffness mismatch [72]. When synthetic galactose-conjugated 
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hydrogels are used to culture hepatocytes, the cells reorganize to spheroids, which is 
important in establishing maintenance of hepatocyte differentiated functions [67].  
 
Figure 2. Ideal requirements for liver tissue engineering scaffolds 
(adapted from [67]) 
 
Figure 2 depicts the ideal requirements to have good and reliable liver tissue 
engineering scaffolds. Basically scaffold mechanical property, cell ligand motif 
presentation, biocompatibility, interconnected porosity and the ability to promote 
spheroids formation are the main requirements. The presentation of galactose on the 
scaffold surface acts to interact with asialoglycoprotein receptor (ASGPR) on the 
hepatocyte membrane to enhance cells retention in the porous scaffold and eventually 
to induce formation of cell aggregates or spheroids. The formed spheroids have been 
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Table 1 summarizes various available galactose containing scaffolds that have 
been investigated as platform to culture hepatocyte as spheroids. One of the examples 
denoted in table 1 is our own in house galactosylated cellulosic sponge which has 
salient feature in quickly aggregating hepatocytes to form spheroids as fast as 7 hours 
post-seeding and higher fold of increase in metabolic activity when compared to other 
galactose conjugate scaffolds. In addition, we have found that primary human 
hepatocyte spheroids cultured in our galactosylated cellulosic sponge are still 
functional and viable up to 40 days post-seeding. 
The fundamental development of our in house cellulosic sponge was initiated by 
the absence of a platform which combines the advantages of having macroporous 
diffusible networks for good mass transfer, soft mechanical stiffness needed to culture 
soft tissues i.e. hepatocytes and the ease of functionalization with cellular 
ligand/modifier. Hydroxypropyl cellulose, a cellulose derivative, is a FDA-approved 
material which has been used as commercial artificial tears material (Lacrisert) [22, 
23]. Hydroxypropyl cellulose and water mixture show interesting temperature 
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sensitive behavior and form biphasic stable state beyond its liquid crystal solution 
temperature (LCST) [81]. This temperature sensitivity is due to hydoxypropyl 
cellulose colloidal nanoparticles response to increasing temperature. The primary 
concept of making porous cellulose hydrogel from cellulose nanoparticle networks 
was introduced in 2000 by Zhibing et al. [14].	  The advantages of making hydrogel 
from nanoparticles networks are it has two levels structural hieararchy e.g. primary 
network of polymer chain and secondary network of cellulose nanoparticles. In 
comparison with other porous gel, the nanoparticle network hydrogel has the 
advantages of highly uniformity and easily tunable mesh sizes. For example, pore size 
in a nanoparticle netwoek can be well controlled by varying either nanoparticle size 
(molecular weight of cellulose used) or the average number of nearest neighbours 
(polymer concentration in solvent) [14]. We hypothesized by combining the 
advantages of hydrogel as soft tissue matrix and porous sponge, we can present proper 
spatiotemporal cues for soft tissue cultures.   
 
2.4 3D hepatocyte culture platforms for drug safety testing 
In the pharmaceutical industry pipeline, new drugs are developed through 
rigorous processes involving compound target validation governing its absorption, 
distribution, metabolism, excretion and toxicity (ADME Tox) (figure 3). ADME 
Tox is a critical step to screen whether a compound target is safe enough to enter 
clinical stage, yet it remains the major challenge for the pharmaceutical industry as 
evidenced by the annual drug withdrawal or severe use limitation of marketed drugs 
due to unexpected adverse effects (lack of efficacy, toxicity, and unfavorable 
pharmacological properties) [82]. Advancements in system biology, genomics, 
epigenetics, bioinformatics and proteomics lead to the fast increase in lead 
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compounds production. This has shifted the importance of ADME Tox prediction to 
before pre-clinical stage, unlike what it usually happened in the past to be done at 
the end stage of pre-clinical stage. Screening lead compounds before pre-clinical 
stage will tremendously save the cost of expensive pre-clinical stages and predict the 
toxicity of the compounds more accurately. Moreover, most of the tested 
compounds are still not massively produced thus still in minute amounts. High 
throughput in vitro platform which only needs minute amount of compound with 
good ADME Tox prediction is highly desired.  Hepatocytes as the cells in the body 
that primarily metabolize and detoxify uptake drugs have been used as the major cell 
model. The importance of using hepatocytes as the cell model is their ability to 
retain species specific drug metabolizing enzymes (cytochrome P450). 
 
 
Figure 3. Drug-discovery pipeline: the ADME Tox strategies are important 




By observing the compound target metabolic profile predicted by hepatocytes 
culture models, one can predict whether the oral administered drugs will be 
metabolized by cytochrome P450 enzymes in the liver before moving to the systemic 
circulation. If the liver-metabolized compound target found to result in toxic by-
product metabolized compounds, one can find an alternative to administer the drugs 
by other route with comparable pharmacological activity. In addition, one can also 
investigate which cytochrome 450 is important in metabolizing certain compound 
[84].  
Various available hepatocyte-based platforms (see table 2) can predict the 
toxicological phenomena of various compound targets. These platforms in general can 
characterize whether the effect of liver metabolism is toxic or not. Thus they are very 
useful tool in evaluating the compound target toxicity. By elucidating the metabolic 
mechanism, one can extend the analysis of the target toxicity from various dose 
concentration, or inter-specific toxicity responses, and from acute to chronic exposure 
[84]. The importance of these hepatocyte-based in vitro platforms is also to bridge the 
gap between animals and humans as well as close prediction the compound toxicity to 
the desired species [84].  In addition, in vitro cell models can replace the animals use 
in safety testing for cosmetics and pharmaceuticals [84]. In Europe, there has been a 









Table 2. Various engineered-liver cell models for in vitro testing of xenobiotics 
(adapted from[84]) 
 
Models Features Refs. 
Sandwich cultures system, 
collagen with collagen, 
collagen with matrigel or 
RGD-galactose 
Polarized cells for studying drug 
metabolism, cytochrome induction, 
transporter activity, acute toxicity and 
idiosyncratic toxicity 
[86, 87] 
3D liver surrogate 
(Regenemed) 
3D Co-cultures of hepatocytes and liver 
stromal cells in nylon scaffolds for 
chronic toxicity and chronic enzyme 
inductions 
[88] 
Spheroid cultures Hepatocyte aggregates formation to 
facilitates bile canaliculi formation and 
study of acute toxicity 
[89] 
Flat-plate bioreactor Perfusion-based system with varying 
oxygen concentration to test zonation-




Shear-mediated signaling by mimicking 
blood flow through the liver with high 
surface to volume ratio, which facilitates 
improved study of cytochrome induction, 





Micro-patterned co-cultures (hepatocytes 
and NIH3T3 fibroblasts) with optimal 
homotypic and heterotypic interactions to 
study chronic toxicity, drug-drug 
interactions, acute toxicity responses and 




Specifically for drug safety testing application, there are some scaffolds which 
are currently available in the market or still being developed by several research 
groups. Those scaffolds are helping the cell function to be maintained by enhancing 
cell to cell contact i.e. 3D spheroid formation. Taking PuraMatrix™ as the first 
interesting example to elucidate, this peptide hydrogel contains nanofibers inspired by 
the fragment of yeast protein design, zuotin, consisting of 16 peptides sequence [95-
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98]. Developed in 1992 by Prof Shuguang Zhang lab in MIT, it has been 
commercialized under company flag 3DM Incorporation since 2003. And now 
PuraMatrix™ gel has been used in several research fields such as stem cells 
differentiation, wound healing assays, angiogenesis assay, and lastly 3D hepatocyte 
spheroid culture with distinctive channels formed in the spheroid [99-102]. However, 
till today there is still no concrete evidence of direct application as multiwell in vitro 
drug testing platform. Essential drawbacks we find to be critical and needs to be 
eliminated are the acidic pH of peptide solution prior to gelation (pH 3.0). The 
requirement for component mixing during gelation can be detrimental to sensitive and 
anchorage dependent cells like hepatocytes.  
Next example of commercially available hydrogel scaffold for 3D cell culture is 
Algimatrix™. Developed by Invitrogen in 2007, this animal-free macroporous 
scaffold is sold in dry state in the well-plate format. Algimatrix™ is synthesized by 
physical crosslinking of alginate matrix. Physical crosslinking is done by mixing 
divalent cation (Ca2+) with the native alginate solution which then creates stiffer 
matrix [103-105]. We realize since the crosslinking is done only by physical ionic 
crosslinking, the scaffold stability over time in culture medium is an issue. Ionically-
crosslinked alginate matrix may undergo ion exchange process during cell culture 
involving loss of divalent cation. This process is generally uncontrollable and 
unpredictable. Therefore Algimatrix™ in this case may not be suitable for hepatocyte 
spheroid culture over prolonged culture. In addition, the divalent cation may diffuse 
into the medium and interfere if used for kidney-tissue cell culture.  
Another polystyrene scaffold which was proposed as in vitro drug testing 
platform, developed by Prof Przyborski in 2004, has also been commercialized under 
company Reinnervate Durham UK (trade name Alvatext scaffold). His research group 
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has gone into simple drug testing trial of cultured HepG2 cells and methotrexate 
(MTX) [106, 107]. HepG2 cells could form cellular aggregates with excellent 
microvili and bile canaliculi formation confirmed by TEM imaging. However, there is 
no special feature in the mechanical stiffness issue and ligands needed for specific 
soft tissue/cell culture and long term culture function maintenance. In addition, we are 
not convinced by how the cells behave in the nanoscale of the polystyrene scaffold 
since there is no significant difference with conventional polystyrene tissue culture 
flask in that scale.  
Latest group to date which is developing inverted colloidal crystal polyacryl 
amine hydrogel scaffold is Kotov’s lab from University of Michigan [108]. They are 
developing uniform macroporous hydrogel polyacryl amine scaffold using polymethyl 
metacrylate spheres as pores template, known as 3D Biomatrix scaffold in the market. 
Hepatocyte spheroid will be uniformly formed and distributed in the pores.  
All the above examples of market available and ongoing research scaffolds for 
3D cell culture platforms mainly function to maintain cell-cell contact and finally 
have 3D spheroid as cell culture model.  
 
2.5 Hepatocyte culture models for hepatitis C antiviral screening 
Hepatitis C virus (HCV) is a major cause of acute and chronic hepatitis in the 
world. Infected HCV patients almost result in chronic hepatitis infection, with 60-
70% of all cases develop active liver diseases and the rests include cirrhosis, end-
stage liver disease and liver cancer. In estimation, 3% of world’s population is 
chronically infected with HCV [109, 110]. Within 20 years of infection, chronic HCV 
patients have developed cirrhosis, which in turn elevate the risk of hepatocellular 
carcinoma and liver failure. This complication of HCV infection has significantly 
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increased the needs of liver transplantation and related mortality [111]. There are 6 
major HCV genotypes exist in the world with approximately three quarters of patients 
with chronic HCV have genotype 1 infection [112]. This majorly affecting genotype 1 
HCV is more resistant to the current available treatments, PEG interferon 2 α and 
ribavirin [110]. There are still no available effective preventive vaccines. Therefore 
there is a strong need to develop new therapies against HCV genotype 1 infection. 
The available standard therapy for chronic HCV infection,  the combination of 
PEG interferon 2 α and ribavirin, still leads to side effect upon 48-week 
administration; the virus sustain its virological responses [113]. In addition to this, 
this combination treatments are often poorly tolerated thus causes other side effects 
such as influenza, cytopenias and neurophyschiatric symptoms [113]. These problems 
had led efforts to combat HCV with different strategies. Instead of combating the 
virus itself, efforts needs to be attempted to disrupt the pathways that the virus 
undertakes to infect the host.  
As shown in figure 4, HCV infects the host cell through some host cell 
glycoprotein receptors. It has been known that HCV exploits human host proteins for 
its own purposes. With these host factors identification for the HCV life cycle, the 
development of new anti HCV vaccine can be greatly sophisticated.  This strategy in 
targeting the host cell proteins enables the broader treatments to combat HCV more 





Figure 4. Many host factors are involved at each step of the HCV life cycle, which 
starts with virus binding to its specific receptors (CD81, Claudin1, Occludin, and SR-
BI/SCARB1). After viral uncoating, the positive-sense HCV RNA is translated and 
also serves as a template for RNA replication and polyprotein translation. Viral RNA 
replication occurs on an altered host membrane compartment known as the 
membranous web; a short list of host factors believed to support web formation and/or 
RNA replication is shown. (adapted from [110]) 
	  
HCV is one of the viruses in Flaviviridae family with single-stranded RNA 
virus approximately 9600 nucleotides in length [114]. As depicted in figure 4, HCV 
infection into the host cell is initiated by the attachment of viral E1/E2 heterodimers 
to the hepatocyte cell membrane. The hepatocyte cellular receptors and co-receptors 
to this infection include glycosaminoglycan, cluster of differentiation 81 (CD81), 
scavenger receptor type B class 1 (SR-B1/SCARB1), Claudin1 and Occludin [115-
119]. The first interaction during HCV infection occurs between glycosaminoglycan 
on the hepatocyte cell surface with HCV virions.  This then continued with binding of 
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CD81 and SCARB1 with HCV E2 envelope protein, at the same time point in viral 
entry [120]. Claudin1 and Occludin, both are tight junctions proteins of polarized 
hepatocytes, act only at the late HCV post-binding step [119]. By understanding these 
host factors involved in the early stage of HCV live cycle, the development of novel 
antiviral leads to the increases in the number of options for combining drug therapy. 
The host specificity of HCV only in chimpanzee and human liver has made the 
study to be greatly challenged over the past decades [121].  It has been hampered by 
the lack of adequate human hepatocyte culture and small animal models [122]. Since 
the use of chimpanzee as HCV infection model is not cost effective and not in tally 
with the efforts to reduce the animal use in research, most efforts are paid towards the 
culture of human liver cells [84]. Huh 7 as cell source in HCV infection model has 
been investigated but found to be lack in	   effective RIG-I-mediated interferon 
production thus unsuitable for innate immunity studies in HCV infection [123]. 
Previously reported cell lines outside the Huh 7 family that are able to support HCV 
infection, are either derived from tumor tissues or immortalized, making them 
incompatible with  research intended to determine potential oncogenic effects of HCV 
infection [124]. Therefore, primary human hepatocytes are still regarded as the gold 
standard in HCV infection elucidation. Primary human hepatocytes in this case need 
to be cultured in a proper system to be polarized over extended culture period, 
because viral entry into the cells is controlled by cell polarization and cellular 
localization of different markers such as cluster of differentiation 81 (CD81), 
SCARB1 and Claudin1 [125, 126]. This presents a challenge to create a robust 3D 
cell culture platform to maintain primary human hepatocyte polarity. There is a need 
to properly recapitulate hepatocyte polarity in the form of cell-dense construct such as 
spheroids which act like artificial human liver tissue. By achieving properly polarized 
28	  
	  
human hepatocyte models in vitro, one can study the HCV infection as well as 
replication over some period of time and thus one can screen new candidate 
compounds for anti viral drugs. The in vitro human hepatocyte model is considered to 
be more economic compared to one other methods of repopulating mouse liver 
ectopically with human hepatocytes, which show its ability to replicate HCV [127]. It 
is described in table 3 various reported 3D cell culture models with different cell 
sources and platforms to show HCV infections. 
 
Table 3. Various engineered-liver cell models for in vitro testing of HCV 
infection study 
Models Features Refs. 
Micropatterned co-culture 
models of primary human 
hepatocyte and stromal cells 
Model showed persistent HCV replication up to 
two weeks of culture but number of infected 
cells were low (~1%) 
[118] 
Matrigel-embedded 3D 
culture of Huh 7 cells as 
spheroids 
Cell lines used as cell model. Localization of 
several HCV receptors e.g. Occludin, Claudin1 
and SCARB1 are still not comparable to those 
observed in primary human hepatocyte 
[4] 
Primary human hepatocytes 
spheroid suspension culture 
Orbital shaker used to form spheroids which 
might not be high throughput. Single patient’s 
HCV derived serum used for viral inoculation. 
[128] 
Human hepatocellular 
carcinoma-derived cell line, 
FLC4 (Functional Liver Cell 
4) cultured in the three-
dimensional radial-flow 
bioreactor 
Carcinoma cells used as cell model. HCV 
receptors were not investigated. Single 
patient’s HCV derived serum used for viral 
inoculation. 
[129] 
3D culture of cell lines 
bearing dicistronic HCV 
RNAs in thermoreversible 
hydrogel 
Carcinoma cells used as cell model. HCV core 
and NS5A proteins expressions were lower 







2.6 Cell source issue in organotypic liver culture models 
 
2.6.1 Primary cells 
Cell source used in the development of in vitro hepatocyte models for both drug 
safety testing and disease models needs to be carefully examined. In this thesis, 
primary hepatocytes, readily available in our lab, were used as the main cell source. 
Freshly isolated primary hepatocytes are the preferred cell model for recapitulating 
the functional responses of the liver, especially for in vitro studies to predict in vivo 
drug metabolism and clearance [87, 131-133]. Although primary hepatocytes could 
offer significant functional benefits, their routine use in cell culture systems also 
imposes challenges. The most significant challenge is the scarcity in obtaining 
primary cells and the tissues from which they are isolated. The quality variability of 
primary human hepatocytes isolated from different patients is another challenge; 
differences in patients’ medical history, genetics and method of isolation can 
contribute to the difficulty in getting reproducible results and comparing results from 
different labs [124}]. Moreover, not all labs have the facility to isolate primary cells in 
routine basis. Hence, currently many commercial vendors have become important 
sources for obtaining primary cells, particularly those of human origin. The advances 
in the cryopreservation technique to store human hepatocytes for long term has 
improved the conveniency and capabilities associated with the use of primary cells, 
removing limitations of the urgency to culture hepatocytes within couple of hours 
post-isolation and enabling repeat experiments using the same batch of cells. When 
properly stored and handled, cryopreserved hepatocytes exhibit similar viability and 
functions after thawing compared to freshly isolated hepatocytes [134-136]. However, 
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finding a reliable commercial source of fresh and or cryopreserved hepatocytes from 
other important toxicology species, such as dog, monkey and mouse, can be 
problematic. Therefore to be widely applicable for others’ routine use, we also have to 
consider other different liver cells such as immortalized cell lines and stem cell 
derived hepatocytes.  
 
2.6.2 Immortalized liver cell lines 
A cell line is a permanently established clonal lineage, sometimes derived from 
hepatoma, where the daughter cells will proliferate unlimitedly in proper medium and 
growth conditions. In contrast to primary cells, cell lines are not confined to a limited 
number of cell divisions due to mutations in one or more growth control pathways 
thus have become immortalized [137, 138]. Liver cell lines are very popular in vitro 
model to study liver function and general mechanisms of toxicity. However, cell lines 
do not contain all the metabolic enzymes, and the enzymes that are present are not at 
their physiological levels thus they are typically unsuitable for drug metabolism and 
toxicity prediction studies [139]. Other drawbacks when using cell lines as the cell 
source in organotypic culture models are the dependence of gene expression on 
several factors such as passage number and genomic instability, hence leading to 
dedifferentiated cells whose phenotype no longer resemble the native cells in vivo 
[139]. 
One of the most commonly used human liver cell line is HepG2 cell, which was 
derived from liver tissue with a well differentiated hepatocellular carcinoma. This cell 
exhibits epithelial-like morphology when cultured as monolayer and cellular 
aggregates. HepG2 cell could secrete typical hepatic plasma proteins like albumin and 
transferrin and is able to perform biotransformation of many, but not all, xenobiotic 
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compounds.  The versatility of culturing HepG2 cell compared to primary human 
hepatocytes makes this cell attractive in various toxicogenomic studies. However, 
comparisons between HepG2 and primary hepatocytes show substantial differences in 
basal gene expression [140-142]. HepG2 show higher expression of genes involved in 
cell cycle regulation, DNA, RNA, and nucleotide metabolism, transcription, transport, 
and signal transduction, and lower transcription levels are associated with cell death, 
lipid metabolism, and xenobiotic metabolism [142]. Basal gene expression levels of 
xenobiotics biotransformation enzymes (CYP1A1, CYP1A2, CYP2C9, CYP2E1, and 
CYP3A4) are substantially lower in HepG2 cell compared to primary hepatocytes 
[142]. The inherent lack of bioactivation potential leads to an underestimation of 
metabolic-dependent toxicity for particular compounds, such as aflatoxin B1, making 
HepG2 cells a less predictive in vitro model system [41, 142, 143]. Some researchers 
have created variants or subclones of HepG2 to address some of these shortcomings 
by transfecting HepG2 cell with constructs which express increased levels of phase 1 
enzymes (such as CYP1A1, CYP1A2, CYP2E1 and CYP3A4) or glutathione-S-
transferases [144, 145]. Therefore, HepG2 and its various subclones that have been 
identified (including C3A) provide a biological model that enables some rudimentary 
approximation of hepatic function that offers some value in certain applications, but 
these cells still could not recapitulate many important aspects of primary hepatocyte 
function and phenotype. In liver disease model, studies of HCV infection in 
hepatocyte cell line HepG2 gave poor result due to inadequate expression of proper 
HCV entry receptors [146] .  
Another popular cell line in organotypic liver culture model is HepaRG, which 
is a cell line derived from adult hepatocellular carcinoma [147].  When cultured in 
monolayer, HepaRG cells consist of two cell types i.e. flattened cell with clear 
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cytoplasm, biliary epithelial cell and primary human hepatocyte-like cell. In order to 
be fully differentiated into hepatocyte-like cell, HepaRG cells must be treated with 
addition of dimethyl sulfoxide (DMSO) at rather high concentration (1%). Fully 
differentiated HepaRG cells exhibit various cytochrome P450 enzymes such as 
CYP1A2, CYP2B6, CYP2C9, CYP2E1 and CYP3A4 significantly higher than 
HepG2 and its subclones. They also exhibit phase 2 enzymes and liver transporters 
normally found in primary human hepatocytes [147-149]. HepaRG cells also express 
receptor pathways involved in xenobiotic metabolism and clearance, including 
constitutive androstane receptor (CAR), pregnane X receptor (PXR), and aryl 
hydrocarbon receptor (AhR). This improved nuclear receptors results in more in vivo-
like expression of CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and 
CYP3A4 enzymes in HepaRG compared to most other hepatic cell lines [148-150]. 
However, the use of high concentration of DMSO (1%) in order to maintain cell 
differentiated state and optimal expression of metabolic enzymes, otherwise the CYPs 
activities decrease, has resulted in the activation of receptor pathways involved in the 
regulation of phase 1 and 2 biotransformation enzymes (e.g. CAR and PXR) [151, 
152]. In these conditions, CYP3A4 enzyme in HepaRG cells is unable to respond to 
drug inducers, such as phenobarbital (PB) and rifampicin (RIF). On the other hand, 
HepaRG cells have shown the promise to be used in HCV infection study; their 
progenitor cells permit HCVpp entry while differentiated cells support long term 
production of infectious HCV particles [153]. Nevertheless, HepaRG still represents 
the most promising surrogate to primary human hepatocytes and has served as a 




2.6.3 Stem cells derived hepatocytes 
The challenges associated with primary hepatocytes and their surrogates have 
sparked interest to use stem cells derived hepatocytes as the cell source in organotypic 
culture.  Both embryonic stem cells (ESCs) and induced pluripotent cells (iPSCs) are 
capable to perform self renewal and retain the ability to differentiate into each of the 
three germ layers (endoderm, mesoderm and ectoderm). Thus these cells theoretically 
can differentiate into any cell lineages [154]. Some researchers have established the 
protocols to differentiate these pluripotent cells towards hepatocytes [154-158]. The 
protocols have a common procedure to initiate the endodermal differentiation process 
that is by adding activin A followed by fibroblast growth factor and Wnt3a to 
facilitate differentiation towards hepatic lineages. Subsequently, hepatic 
differentiation is facilitated by treatment with cocktails mixture of hepatocyte growth 
factor, epithelial growth factor, oncostatin M and fibroblast growth factor [159], and 
by increasing cellular confluency [160, 161]. The advantage of using cells that are 
derived from adult source i.e. iPSCs is their ability to create donor pool that is pre-
selected thus represent polymorphic variants within a target population. This 
advantage is difficult to achieve with primary cells.  
Despite the advantages in sourcing and expansion of these stem cell derived 
hepatocytes, limitations still exist such as the persistent fetal phenotype exhibited by 
these cells [159, 162], although the current iPSCs based approaches managed to 
minimize this effect [157, 163]. From the perspective of drug safety testing, it is 
important that the cells used as hepatocyte source to have expression of phase 1 and 2 
enzymatic activities, as well as uptake and efflux transporter activity. To date, all stem 
cell based approaches still exhibit suboptimal phase 1 activity, with no clear 
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information on phase 2 or transporter activity [162]. Reported deficiencies in phase 1 
enzyme activity in stem cell populations could be triggered by the heterogeneity of 
the differentiated cell lineages population, as purified populations actually exhibit 
CYP3A4 activity at levels similar to those in primary human cells [164]. Human 
hepatocyte-like cells derived from iPSCs have been reported to support the complete 
HCV life cycle including inflammatory response of infection, thus enabling study of 

















DEVELOPMENT OF GALACTOSYLATED CELLULOSIC SPONGE FOR 3D 
HEPATOCYTE CULTURE AND DRUG SAFETY TESTING 
 
3.1 Introduction 
The content of this part of the thesis is slightly modified from author own 
published paper [80] and permission to reproduce full article had been obtained (see 
appendix). The early development of cellulosic sponge as cell culture platform has 
shown the salient features of this sponge in creating 3D cell microenvironments 
within its macroporous hydrogel networks [15, 166]. The chemical property of the 
cellulosic sponge raw material, FDA-approved hydroxypropyl cellulose (HPC), has 
offered the ease of functionalization of its side chain group with different cell ligands. 
The needs to have a proper surface chemistry in the 3D cell culture scaffold have been 
facilitated by this chemical versatility. In liver tissue engineering, one of the widely 
studied cell construct is spheroids which are formed by the interaction of conjugated 
galactose on a cell culture substrate with hepatocyte membrane asialoglycoprotein 
receptor (ASGPR).  
Spheroids are three-dimensional multi-cellular aggregates that exhibit a high 
degree of cell-to-cell contact. Compactness of cells contained in 3D spheroids in vitro 
preserve complex in vivo cell phenotypes which are otherwise absent in conventional 
2D cultures [167, 168]. 3D multi-cellular spheroids have been useful in multiple 
applications including stem cell, cancer biology and tissue engineering research [95, 
169-171]. In 3D hepatocyte spheroids, tight cell-cell junctions help sustain cell 
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viability for extended culture periods and maintain high level liver-specific functions 
e.g. albumin secretion, urea synthesis and cytochrome P450 activity [25, 172]. These 
attributes make 3D hepatocyte spheroids potentially attractive for in vitro drug safety 
testing.  
Growing spheroids using previously described methods such as by hanging drop, 
centrifugation, on 2D substrates, or in suspension culture are limited since these 
methods provide no means of physical spheroid constraint during extended culture. 
Consequently there is difficulty in controlling spheroid size and in manipulating 
floating spheroids for cell-based drug safety testing applications [173-176]. When 
smaller spheroids collide to form larger spheroids in culture, mass transfer of oxygen, 
nutrients, metabolites and drugs can be impeded in the inner core yielding high 
variability during drug safety testing [175]. Attempts to constrain 3D spheroids in a 
diffusible dimension have been achieved by growing spheroids on microfabricated 
platforms [177, 178], polyurethane foams [179, 180], and polymeric scaffolds [108], 
but these methods do not provide the optimal chemical and mechanical 
microenvironments needed to maintain high-level cellular functions. Furthermore, 
scalability in manufacturing and simplicity in operation for high-throughput, large-
scale drug safety testing applications is also problematic.   
To address these concerns we have constrained hepatocyte spheroids in a 
macroporous network of a soft galactosylated cellulosic sponge.  The macroporosity 
of the sponge provides control over spheroid size while the conjugated galactose 
ligands present chemical cues to the cells to form spheroids. The soft hydrogel-based 
sponge would be proper to maintain mature hepatocyte differentiated functions via 
control of the matrix rigidity [181].  The configuration of the sponges supports high-
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throughput applications and ease of use, similar to readily available 2D culture 
platforms.  Sponges are fabricated in bulk and sliced thin to minimize drug absorption. 
Hepatocyte spheroids grown in the sponge can maintain 3D cell morphology, cell-cell 
interactions, polarity, transporter expression, excretion and metabolic functions; and 
exhibit in some cases improved CYP450s enzyme activities. 
 
3.2 Materials and Methods 
3.2.1. Materials 
All chemicals and reagents were purchased from Sigma Aldrich (Singapore), 
unless otherwise stated.  
3.2.2 Chemical synthesis of galactosylated hydroxypropyl cellulose allyl (HA Gal) 
Hydroxypropyl cellulose (HPC), Mw = 80,000 g/mol and ~3.4 degree of 
etherification was dehydrated by azeotropic distillation in toluene. 4 grams of dried 
HPC was dissolved in anhydrous chloroform (100 mL), to which 2.095 mL allyl 
isocyanate 98% and 1 mL dibutyltin dilaurate 95% were added dropwise. The mixture 
was stirred vigorously for 48 hours at room temperature, after which it was 
precipitated in an excess amount of anhydrous diethyl ether.  Following vacuum 
drying, the product was dissolved in deionized water (DI H2O), purified by dialysis 
for 3 days, and finally lyophilized to the intermediate product, hydroxypropyl 
cellulose allyl (HA). For galactose conjugation, 1 gram of HA was dissolved in 15 mL 
anhydrous dimethyl formamide (DMF) in which the hydroxyl groups were activated 
by addition of 1,1’-carbonyldiimidazole (0.322 g in 2 mL DMF).  D-(+)-
galactosamine HCl ( 0.427 g in 30 mL DMF), which was dissolved with addition of 
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triethylamine, was added to the mixture with two folds molar ratio compared to D-
(+)-galactosamine HCl. The reaction was carried out for a further 48 hours at room 
temperature. To remove impurities, the mixture was further dialyzed in excess 
methanol and subsequently in deionised water for 3 days each and the final product 
(hydroxypropyl cellulose allyl galactose, HA Gal) was lyophilized.  A schematic 
diagram with the complete synthesis described, including 1H NMR characterization 
are shown in figures 5 and 6. 
3.2.3 Preparation of HA Gal sponges 
HA Gal was dissolved in deionised water to a final concentration of 7.5 % 
wt/vol after which the solution was inserted into tubes (diameter 6 mm, length 3 cm). 
The tubes were heated in a water bath (40°C) until phase separation occurred, and 
then crosslinked by γ irradiation for 30 min at a dose of 10 kGray/hour (Gammacell 
220, MDS Nordion, Canada). The sponge monoliths were obtained by breaking tubes 
subsequent to freezing in dry ice. A Krumdieck tissue slicer (Alabama Research & 
Development USA) was used to cut the sponge uniformly (50 rpm for 1 mm 
thickness). We fabricated thin sponge slices to reduce possible drug absorption during 
assays. Sliced sponges were washed extensively with excess amounts of deionised 
water for 3 days to remove uncross-linked polymers. Finally, slices were lyophilized 
and sterilized by γ irradiation (1.7 kGray total dose) prior to cell seeding with 
hepatocytes.  A schematic diagram of the sponge preparation is described in figure 6. 
As a comparison, galactosylated polyethylene terephthalate (PET Gal) 
membranes were also seeded with hepatocytes.  Preparation and synthesis steps of 
PET Gal membranes have been described previously [175]. 
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3.2.4 Physiochemical characterization of HA Gal macroporous sponges 
3.2.4.1 High performance liquid chromatography elution assay 
Galactose presence in the sponge was detected by a HPLC elution assay. 
Sponges were hydrolyzed by 6 N HCl at 110°C for 24 hours. Cooled hydrolyzed 
solutions were evaporated, re-suspended in 500 µL deionised water and derivatized 
using the ATTO-TAG™ CBCQA amine-derivatization kit (Molecular Probes, USA) 
for fluorescence detection on a C-18 column using HPLC (Agilent Technology, place). 
The mobile phase consisted of A) water + 0.1 % trifluoroacetic acid (TFA), and B) 
acetonitrile + 0.1 %TFA with an A/B gradient (98:2/ 70:30 in 45 min. The flow rate 
was 1 mL/min and the fluorescence detector settings were excitation at 450 nm, and 
emission at 550 nm. 
3.2.4.2 X-Ray photoelectron spectroscopy 
X-Ray photoelectron spectroscopy was used to qualitatively verify galactose 
ligand conjugation onto the HA chemical backbone.  Measurements were made on a 
VG ESCALAB Mk II spectrometer with a MgKa X-ray source (1253.6 eV photons) 
at a constant retard ratio of 40.  
3.2.4.3 Scanning electron microscopy  
Top and cross section views of the sponge surface morphology and porosity 
were captured using SEM (JEOL JSM- 5600, Japan) at 10 kV. High magnification of 
SEM (15,000 folds) was performed to observe the sponge surface structure. Prior to 
imaging, the dried sponge was sputter coated with platinum for 60 seconds. Pore size 
distribution of the sponges was quantified with Image J software (version 1.43u) from 
collective SEM top view images of the sponges. 
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3.2.4.4 Water uptake and sponge porosity measurements 
The lyophilized sponges were soaked in deionised water at room temperature 








= , where Wh is the hydrated weight and Wd is the 
dehydrated weight. The porosities of lyophilized HA Gal sponges were determined by 
solvent replacement. Samples were soaked in absolute ethanol for 24 hours and 
weighted after excess ethanol on the surface was blotted. It was noted that there were 
no significant changes in dimension before and after immersion in ethanol. The 





= , where M1 and M2 are the 
weight of sponge before and after immersion in absolute ethanol, respectively; ρ is the 
density of absolute ethanol and V is the volume of sponge.  
3.2.4.5 Elastic modulus measurement 
The elastic modulus of the sponge was measured by atomic force microscopy 
(Bioscope Catalyst, Veeco Instruments, Santa Barbara, CA) in deionized water. A 
hybrid Atomic Force Microscopy (AFM) probe consisting of a silicon nitride 
cantilever and a silicon tip (ScanAsyst-Fluid, Veeco Probes, Camarillo, CA) was used. 
The deflection sensitivity was calibrated by ramping force-distance curves on a glass 
surface, and the spring constant was calibrated by the thermal noise method. After 
calibration, 128 x 128 force-distance curves were recorded over an area of 5 µm x 5 
µm by force volume. Each force-distance curve was analyzed by fitting to the Hertz 
model with conical tip geometry and Poisson ratio of 0.5. The obtained elastic moduli 
from each force-distance curve were mapped into a bitmap image with 128 x 128 
pixels. The curve fitting and statistical analysis was implemented by a self-developed 
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Fortran program.  The relationship between elastic modulus with the measured force 






= , where F is the measured force, E is Young’s 
elastic modulus, v is the Poisson ratio of the material under measurement (0.5 was 
used in the data processing), α is the half angle of the probe (22°) and δ is the sample 
deformation/indentation.  
3.2.4.6 Zeta potential measurement 
HA Gal solutions in deionized water with different concentrations (0.125 to 
2.5 %wt/vol) were heated to 50°C to let the phase separation occur. The zeta 
potentials were measured using Malvern Zeta Sizer Nano ZS 90 (Malvern Instruments, 
United Kingdom) normalized to the base potential of water.   
 
3.2.5 Hepatocyte isolation and culture 
Hepatocytes were isolated from male Wistar rats weighing 250-300 g using a 
modified in situ collagenase perfusion method [182]. Animals were handled 
according to the IACUC protocols approved by the IACUC committee of National 
University of Singapore. Cells were maintained with Williams’ E medium 
supplemented with 10 mM NaHCO3, 1 mg/mL BSA, 10 ng/mL of EGF, 0.5 mg/mL 
of insulin, 5 nM dexamethasone, 50 ng/mL linoleic acid, 100 units/mL penicillin, and 
100 mg/mL streptomycin and were incubated with 5% CO2 at 37°C and 95 % 
humidity. Medium was replenished every two days. Viability of hepatocytes was 
determined to be >90% by the Trypan Blue exclusion assay. Yields were 
approximately 108 cells per rat.  Freshly isolated rat hepatocytes (105 cells in 10 µL 
culture medium) were loaded to the centre of the wells in 48-well plates; the sponges 
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were immediately inserted into the wells to allow cells to be absorbed into the 
sponges from the lower surface. Another aliquot of 105 cells in 10 µL culture medium 
was then seeded into the sponge by dropping the cell suspension onto the top sponge 
surface. The cell suspension was absorbed into the sponge interior due to the inherent 
hydrophilicity of the sponges. Fresh culture medium was added to the sponge edge 
after 45 minutes incubation (300 µL per sponge in 48-well plate). Hepatocytes seeded 
on a collagen sandwich platform (0.29 mg/mL collagen concentration) were used as 
control as reported previously [183]. 
 
3.2.6 Hepatocyte spheroids characterization 
3.2.6.1 Spheroids size distribution 
Spheroid size distribution was quantified using imageJ software (version 1.43u) 
from collective phase contrast images of living hepatocyte spheroids cultured on the 
PET galactose membrane and in the HA Gal sponges on day 1, 3 and 6. 
3.2.6.2 Scanning electron microscopy 
Hepatocyte spheroids in sponges on day 1, day 3 and day 7 were fixed with 2.5 
% glutaraldehyde overnight and stained with 1% OsO4 for 1 h. Samples were then 
dehydrated step-wise with ethanol (25 %, 50 %, 75 %, 90 % and 100 %) for 10 
minutes each, dried in a vacuum oven and sputter coated with platinum for 60 seconds. 
The samples were viewed with a scanning electron microscope (JEOL JSM- 5600, 





3.2.6.3 Live/dead staining 
Hepatocytes spheroids were co-stained with Cell Tracker Green (CTG, 20 µM) 
(Molecular Probes, USA) and propidium iodide (PI, 25 µg/mL) (Molecular Probes, 
USA) to determine live and dead cells, respectively. Cells were incubated for 30 min 
at 37°C and then fixed with 3.7 % paraformaldehyde for 30 min at room temperature. 
Fluorsave (Merck Chemicals) was applied to the stained spheroids to minimize photo-
bleaching. Images were acquired by confocal laser scanning microscopy (Zeiss 
LSM510, Germany) at 488 and 543 nm excitation wavelengths.  
3.2.6.4 Time lapse imaging of spheroids formation 
The dynamic process of hepatocyte spheroid formation in the sponges was 
monitored immediately upon cell seeding. Hepatocytes were pre-stained with 20 µM 
Cell Tracker Green (Molecular Probe, USA) for 20 min prior to seeding. Seeded 
sponges were imaged consecutively for 12 hours using a Delta Vision system 
(Applied Precision, USA) equipped with nano-positioning and a controlled 
temperature chamber set at 37°C and 5 % CO2.  Images were acquired in hourly 
intervals thereby minimizing light exposure to the cells. 
 
3.2.7 Hepatocyte functional assessments 
3.2.7.1 Immunofluorescence microscopy 
To stain F-actin, E-cadherin and MRP2/CD147, hepatocytes cultured for 48 
hours in the sponges were fixed in 3.7 % paraformaldehyde for 30 min. For staining 
F-actin, the cells were permeabilized for 5 min in 0.1 % Triton X-100 and incubated 
with 1 µg/mL TRITC-phalloidin (Molecular Probes, USA) for 20 min. For E-cadherin, 
44	  
	  
the cells were permeabilized with 0.1 % Triton X-100 for 30 min, blocked with 1 % 
BSA for 30 min, incubated with mouse anti-rat E-cadherin (BD, USA) overnight at 
4°C followed by incubation with a FITC conjugated anti-mouse secondary antibody.  
For MRP2/CD147 staining, the cells were permeabilized with 0.1% Triton X-100 for 
30 min, blocked with 1% BSA for 30 min, incubated with rabbit anti-rat MRP2 
(Sigma Aldrich, Singapore and mouse anti-rat CD147 (Serotec, USA) overnight at 
4°C  and eventually incubated with FITC conjugated anti-mouse and TRITC 
conjugated anti-rabbit secondary antibodies. For all staining procedures, at the end of 
staining period Fluorsave (Merck Chemicals) was applied to preserve the dyes from 
bleaching. Microscopy images were acquired with 20x lens on a Zeiss Meta 510 
upright confocal microscope. The 3D image stack was reconstructed using LSM 
Browser.  
3.2.7.2 Transmission electron microscopy  
Hepatocyte spheroids in sponges were fixed with 3.7% paraformaldehyde for 30 
min and treated with 1% OsO4 for 2 hours at room temperature. Samples were 
subsequently dehydrated step-wise with ethanol (25 %, 50 %, 75 %, 95 % and 100 %) 
for 10 min followed by 100% acetone twice for 20 min each. Upon dehydration, 
samples were then treated with 1:1 ratio mixture of acetone and araldite resin for 30 
min at room temperature followed by overnight treatment at a 1:6 ratio at room 
temperature. On the following day, the samples were placed into araldite resin for 30 
min at room temperature before transferring into a 40°C oven for another 30 min. 
Araldite resin was subsequently changed followed by 1 hour subsequent treatments at 
45°C and 50°C.  Lastly, the samples were embedded with araldite resin at 60°C for 24 
hours. Sections of 90-100 nm thickness were sliced using a Leica EM UC6 
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Ultramicrotome, collected onto 200-mesh copper grids and co-stained with uranyl 
acetate and lead citrate for 10 min each. Observation was undertaken with a 
Transmission Electron Microscope (TEM) (JEOL JEM-1010, Japan) at voltage 100 
kV. 
3.2.7.3 Biliary excretion of fluorescein dye 
For monitoring hepatocyte repolarization, we visualized the excretion of 
fluorescein dye via bile canaliculi. Hepatocytes spheroids were incubated with 
15 µg/mL fluorescein diacetate (Molecular Probes, USA) in Williams’ E medium at 
37 °C for 45 min at different time intervals (16 hours, 24 hours and 48 hours) post-
seeding. The cultures were then rinsed and fixed with 3.7 % paraformaldehyde for 30 
min before viewing with a 20x lens on a Zeiss Meta 510 upright confocal microscope.  
3.2.7.4 Albumin secretion & urea synthesis assays 
Albumin secretion by hepatocytes on days 1, 3, 5 and 7 were assayed using a rat 
albumin enzyme-linked immunosorbent assay quantitation kit (Bethyl Laboratories 
Inc., Montgomery, Texas). Urea synthesis by cultured hepatocytes in William’s E 
medium spiked with 1 mM NH4Cl for 90 min was assayed on the same days using a 
Urea Nitrogen Kit (Stanbio Laboratory, Boerne, Texas). All functional data were 
normalized by the number of cells seeded in the sponges which was quantified using 






3.2.8 Drug inducibility of hepatocyte spheroids 
3.2.8.1 Reverse transcriptase polymerase chain reaction  
RNA was extracted from hepatocytes cultured as 3D spheroids in HA Gal 
sponges by TRIzol (Invitrogen, Singapore). Total RNA concentration was quantified 
by a Nanodrop (Thermoscientific) and 1 µg of RNA was converted to cDNA by High 
Capacity RNA-to-cDNA (Applied Biosystems). Primers were designed using Primer 
3 and real-time PCR was performed by using SYBR green fast master mix on a ABI 
7500 Fast Real-Time PCR system (Applied Biosystems). Gene expression was 
calculated using the ΔΔCT method normalized to GAPDH. The primers used in 
experiment are shown below.  
Table 4. Primer sequences used in RT-PCR experiments 
CYPs 



































































Mdr1a: Multi-Drug Resistance 1a, Mrp2: Multidrug Resistance Protein 2, Ntcp: 
Na/taurocholate Co-transporting Polypeptide, Bsep: Bile Salt Export Pump, Oatp1: 
Organic Anion Transporting Polypeptide 1 
P.S.: Product size, Annealing temperature: 60°C, Cycle numbers: 40 
3.2.8.2 CYP450 induction study 
Hepatocyte spheroids cultured in the sponges were used to study drug induction 
of three CYP450 enzymes, i.e. CYP1A2, CYP2B2 and CYP3A2. 72 hours post-
seeding, cells were incubated at 37°C with Williams’ E medium containing inducers 
(50 µM β-naphthaflavone, 1A2; 1 mM phenobarbital, 2B2; 50 µM pregnenolone-16α-
carbonitrile, 3A2). After 48 hours of induction, medium was removed and the cells 
were further incubated for 2 hours at 37°C with Krebs-Henseleit- bicarbonate (KHB) 
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buffer (118 mM NaCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 4.7 mM KCl, 26 mM 
NaHCO3, and 2.5 mM CaCl2) containing the P450 substrates (200 µM phenacetin, 
1A2; 200 µM bupropion, 2B2; and 5 µM midazolam, 3A2) after which the 
supernatants were collected as samples. The drug metabolite product in the 
supernatant was assayed from induced and vehicle- (0.1% DMSO) treated 
hepatocytes cultured in HA Gal sponges or in the collagen sandwich cultures. 
Detected metabolite products for CYP1A2, CYP2B2 and CYP3A2 were 
acetaminophen (APAP), hydroxy bupropion (OH-bupropion) and hydroxy midazolam 
(OH-midazolam), respectively. Cell supernatants (300 µL) were added with 50 µL 
internal standards (100 ng/mLAPAP-D4 for APAP and 1’-OH-midazolam, 100 
ng/mL OH-bupropion-D6 for OH-bupropion) and dried by concentrator under 
vacuum. The obtained residues were reconstituted in 50 µL methanol containing 0.1 
% formic acid and centrifuged at 10000 rpm for 10 min. The supernatants were then 
analysed by Liquid Chromatography-Mass Spectrometry (LC-MS Finnigan LCQ 
Deca XP Max, Agilent 1100 series).  The LCMS experiments setup consisted of a 
flow rate of 0.8 mL/min, with solvent A, 0.1% formic acid in water, and solvent B, 
0.1% formic acid in methanol.  The column used was a Phenomenex Onyx-monolithic 
C18 with dimensions of 100 x 3.0 mm. The mass spectrometry parameters were spray 
voltage 5 kV, sheath gas flow rate of 80 L/min, auxiliary gas flow rate set at 20 L/min, 
capillary temperature of 350°C, tube lens 45 V, and capillary voltage 30 V.  Elution 
schemes for the three different metabolites products were for APAP and OH-
midazolam, solvent B gradually increased from 6% to 90% in 6 min while for OH-




3.2.9 Drug absorption properties of sponge 
Sponges were incubated with various hydrophobic and hydrophilic drugs with 
different net charges dissolved in PBS for 24 hours at 37°C. The concentrations of 
each compound before and after incubation were recorded with UV 
Spectrophotometer (Agilent).  Percentage of drug absorption was determined by the 





3.2.10 Statistical analysis 
Statistical comparisons were undertaken using paired two-tailed Student’s t tests. 
Results are expressed as mean ± standard error of the mean (s.e.m).  Confidence 
interval to be significantly different is 95%.  
 
3.3 Results  
3.3.1 Galactosylated macroporous cellulosic sponges have macroporosity for the 
confinement of hepatocyte spheroids 
The first step in the chemical synthesis of the macroporous cellulosic sponges 
involved the conjugation of allyl groups onto hydroxypropyl groups of hydroxypropyl 
cellulose to act as crosslinking sites during γ irradiation, as described elsewhere [15]. 
The galactose conjugation onto the remaining available hydroxypropyl groups was 
performed using 1,1’-carbonyldiamidazole in anhydrous dimethylformamide (fig 6A). 




Figure 5. a) Chemical synthesis steps, b) Schematic diagram of galactosylated 
cellulosic sponge preparation  
 
Galactose presence on the chemical backbone was verified by 1H NMR by 
identifying additional peaks at ~7 to 8 ppm which indicates additional bonds from the 
attached galactose (fig 6). The integrated peak area between 2.5 ppm to 5 ppm 
showed an increase from 2.067 to 2.402 relative amount of the proton, which 
correlated to the presence of more hydroxyl groups from the conjugated galactose 




Figure 6. Chemical synthesis validation with 1HNMR spectrum of galactosylated 
cellulosic sponge in d6-acetone. Alphabetic labels correspond to figure 5A. 
 
To further confirm the presence of galactose in the sponges, we hydrolyzed the 
sponges with 6N hydrochloric acid at 110°C for 24 hours, derivatized using an amine-
derivatization kit and analyzed the products using HPLC. As a comparison, a pure D-
(+)-galactosamine sample was also assayed. One eluted peak in the HPLC 
chromatogram at ~43 min represents the bound galactose (figure 7A) [175]. An X-ray 
photoelectron spectroscopy spectrum showed increased nitrogen atomic counts after 
conjugation (~1.5 % increase) (figure 7B). Lectin conjugated with FITC was also 
used to specifically stain galactose on the sponge surface and showed increased FITC 
signal, compared to non-galactose containing HA sponges (data not shown). From the 
point of view of the galactose conjugate into HA side chain group, this equimolar 




Figure 7. Characterization of cellulosic sponge: a) Galactose elution assay with High 
Performance Liquid Chromatography (HPLC). Red circle indicates the elution time. b) 
X-ray Photoelectron Spectroscopy 
 
Surface morphology and porosity of the sponges were characterized using SEM. 
Image analysis of the sponge porosity showed the average pore size to be between 
110 to 130 µm (figure 8A) for potentially constraining cellular spheroids within 
diffusible dimension [29, 184]. Water uptake of the HA Gal sponge is 95.90 ± 0.19 % 
with porosity 89.76 ± 8.50 %. Measurement of the elastic modulus of the sponges 
using atomic force microscopy revealed an average modulus of 5.6 kPa (figure 8B). 
This modulus is considered to be soft and close to the modulus of native rat and 
human livers [185, 186]. The net charge of the HA Gal structure in deionized water 
was measured through zeta potential measurement of the HA Gal at different 
concentrations ranging from 0.125 to 2.5 %wt/vol (figure 8C).  At 2.5% wt/vol the 
value approached an almost neutral charge (-0.91 mV), which at concentrations 





high viscosity. Therefore, at the working concentration for cell culture (7.5 %wt/vol), 
the value is considered to be a neutral net charge.  
 
Figure 8. Characterization of cellulosic sponge: a) Sponge pore size distribution 
(n=40), b) Elastic modulus measurement by Atomic Force Microscope (AFM) (n=3), 
c) Zeta potential measurement (n=3). Data are average ± standard deviation 
In addition to the macroporous structure viewed from the top of the sponges, the 
porosity also expanded throughout the sponges cross sectional areas (figures 9A-B). 
High magnification images of the sponge surface revealed surface sub-micron 
features in the nanometer scale which might tether the hepatocyte spheroids to the 
sponge (figure 9C). The dry sponge was incubated in fluorescein isothiocyanate 
solution to stain the sponge’s macroporous structure in aqueous phase. By laser 
confocal microscopy, we observed that the macroporosity was maintained as a 
hydrated macroporous network structure in an aqueous environment (figure 9D) in 




Figure 9. Characterization of cellulosic sponge: a) SEM image of cross section view, 
b) SEM image of top view, c) SEM image of sponge surface sub-micron features and 
d) Confocal image of FITC-stained sponge  
 
3.3.2 Characterization of the hepatocyte spheroids cultured in cellulosic sponges  
3.3.2.1 Hepatocyte spheroids develop more rapidly in cellulosic sponges and 
maintain cell viability 
Rat hepatocytes cultured on three different platforms revealed platform-
dependent cell behaviours (figure 10).  Hepatocytes cultured on collagen monolayers 
were relatively flat and spread on day 3 onwards, which correlate with loss of 
differentiated functions [175]. Hepatocyte spheroids formation on galactosylated 
polyethylene terephtalate membranes (2D PET Gal membrane) took 3 days to form, 
and often collided with adjacent spheroids thus forming larger spheroids. In the HA 
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Gal sponge cultures, hepatocytes immediately organized into 3D spheroids within 1 
day of culture, and remained stable in this configuration until at least day 6. 
Hepatocyte spheroids formed in the HA Gal sponges were smaller than those formed 
on 2D PET Gal membrane, with spheroid diameter 60.7 ± 15.9 µm and 108.1 ± 19.2 
µm, for each platform, respectively.  In addition, spheroids formed in HA Gal sponges 
were constrained by the sponge pores and thus did not easily detach as those plated on 
2D PET Gal membranes.  
Figure 10. Phase contrast images of rat hepatocyte cultured in 3 different platforms 
(scale bar 100 µm). Diameter of hepatocyte spheroids formed on PET Gal membrane 
on day 3: 39.8 ± 8.1 µm, day 6: 108.1 ± 19.2 µm, and in HA Gal Sponge day 1: 46.1 
± 9.3 µm, day 3: 55.7 ± 21.1 µm, day 6: 60.7 ± 15.9 µm. (n=15)  
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Hepatocyte spheroids cultured between days 1 and 7 showed gradual increases 
in surface smoothness and disappearance of the cell-cell boundaries (figure 11). On 
day 1, the cell morphology was spherical. The nature of the hydrophilic and soft 
hydrogel sponges would prevent the cells from spreading, which normally occurs on 
hard substrates [181]. Tethered spheroids on the sponge surface was observed (figure 
11).  The arrows in the figure show the contact points where the spheroids adhere to 
the sponge surface sub micron features.  
 







Hepatocyte spheroid viability, which was assessed by co-staining live and dead 
cells using Cell-Tracker Green (CTG) and Propidium Iodide (PI), respectively, 
showed no PI signal which revealed good viability maintenance from day 1 to day 7 
in culture (figure 12). The CTG signals illustrated indistinguishable borders between 
single cells in the spheroids, which reflected the tightness of the cell-cell contacts.  
Figure 12. Hepatocyte spheroids viability (projected spheroids images, scale bar 20 
µm) 
 
Dynamic observation of hepatocytes upon seeding into the sponges for the first 
12 hours showed that by 7 hours, the cells had reorganized themselves into hepatocyte 
spheroids with no further detectable changes in cell movement (figure 13). The 
spheroid morphology appeared compact and with cell boundaries becoming 
indistinguishable after 7 hours. 
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Figure 13. Time-lapse imaging of hepatocyte spheroids formation in HA Gal sponge 
(scale bar 100 µm) 
 
3.3.2.2 Hepatocyte spheroids in cellulosic sponges maintain polarized phenotypes 
Immunofluorescence staining of F-actin, E-cadherin and MRP2/CD147 in the 
hepatocyte spheroids 48 hours post seeding, in comparison to collagen sandwich 
control, showed localization of these markers (figure 14). As would be expected in 
non-spreading cells, F-actin staining revealed that the actin cytoskeleton had a 
predominant cortical localization in both sponge and collagen sandwich cultures and 
an absence of stress fibers. E-cadherin staining, a marker of cell-cell adhesions 
demonstrated that cells in the hepatocyte spheroids have tight associations between 
neighbouring cells.  E-cadherin expression also supports the maintenance of cell 
viability during long-term culture [187].  MRP2/CD147 staining marked the apical 
and basolateral domains of the hepatocytes, respectively. In MRP2/CD147 staining 
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image (figure 14 rightmost panel), the signals showed a comparable and non-
colocalized signal as observed in collagen sandwich culture. 
Figure 14. Immunofluorescence staining of polarity markers and cell-cell adhesions 
of hepatocyte spheroids (projected spheroids images, scale bar 20 µm) 
 
Ultrastructural views observed by transmission electron microscopy illustrated 
the sub-cellular micro-structures located inside the spheroids.  The images of 
hepatocyte spheroids cultured for 48 hours demonstrated a space between 
neighbouring cells, reminiscent of the bile canaliculi with the presence of microvilli in 





Figure 15. i-ii) Transmission electron microscopy images of hepatocytes spheroid at 
48 hours post-seeding and iii) Rat liver transmission electron microscopy image 
(adapted from [190]). Scale bars for i, ii and iii are 1, 0.5 and 0.75 µm, respectively. 
TJ: Tight Junction, BC: Bile Canaliculi, Mv: Microvili, M: Mitochondria 
 
3.3.2.3 Hepatocyte spheroids in cellulosic sponges show maintained liver-specific 
functions over time 
Several liver functions are thought to be dependent on the polarized phenotype 
of the cells, including biliary excretion, albumin secretion and urea synthesis. After 
we observed an early formation polarity of hepatocytes in the cellulosic sponges, we 
wanted to address if these functions were also enhanced.  
Biliary excretion was examined by the addition of fluorescein diacetate dye at 
various time intervals, including 16, 24 and 48 hours post seeding (figure 16).  
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Polarized hepatocytes formed bile canaliculi structures between neighbouring cells 
that contain the MRP2 transporter (see figure 14). Viable cells in the spheroids will 
cleave FDA into fluorosecein dye by intracellular esterases which then be excreted by 
MRP2 into the bile canaliculi. FDA staining in the hepatocyte spheroids formed in the 
sponge showed an accumulation in the bile canaliculi between two cells, starting from 
16 hours post seeding, significantly faster than has been reported in collagen 
sandwich which normally occurs between 48-72 hours post-seeding [191]. 
Morphology of the FDA signal resembled the mouth-like shape of bile canaliculi 
described elsewhere [2, 192], confirming its proper excretion.  
 
Figure 16. Fluorescein diacetate excretion of hepatocytes in collagen sandwich (CS) 
and sponge (HA Gal) at different time intervals (projected spheroid images, scale bar 
20 µm) 
 
Maintenance of albumin secretion and urea synthesis, markers of mature 
differentiated hepatocytes, during extended culture is a prerequisite for drug safety 
testing applications [193]. Figure 17 demonstrates that these functions were generally 
62	  
	  
better maintained in hepatocytes cultured in the HA Gal sponge compared to the 
collagen sandwich for at least 7 days. When the hepatocytes were cultured in collagen 
sandwich, they had albumin secretion rate ranging from 57.74 µg/ million cells/ day 
to 219.70 µg/ million cells/ day for 7 days of culture. Hepatocytes cultured in the 
sponge on average secreted albumin at the rate ranging from 127.51 µg/ million cells/ 
day to 1,145 µg/ million cells/ day, showing their peak on day 5 (figure 17 left panel). 
There was a decrease of secretion to 908.95 µg/ million cells/ day on day 7.  Urea 
synthesis capability of hepatocytes cultured in the sponge showed an increasing trend 
from day 1 to day 7 of culture (figure 17 right panel), ranging from 71.31 µg/ million 
cells/ 90 min to 666.44 µg/ million cells/ 90 min. On average, hepatocytes cultured in 
collagen sandwich showed relatively stable and lower urea synthesis rate at the range 
of 30.52 µg/ million cells/ 90 min to 40.52 µg/ million cells/ 90 min.   
Figure 17. Albumin secretion and urea synthesis function of hepatocyte in the 
sponges and collagen sandwich. Data are average ± standard error of the mean from 3 
independent experiments 
 
3.3.2.4 Drug-metabolizing enzymes and transporters are maintained over time in 
hepatocytes cultured in cellulosic sponge 
Maintenance of drug-metabolizing enzymes (CYP1A2, CYP3A2, CYP4A1, 
CYP2B2 and CYP2E1) and drug transporter expression (Mdr1a, Mrp2, Ntcp, Bsep 
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and Oatp1) was examined in hepatocyte spheroids and compared to sandwich culture. 
Hepatocyte spheroids showed higher expression of CYP1A2, CYP3A2 and CYP4A1 
than the hepatocytes cultured in collagen sandwich (figure 18 upper panel). The 
expression of CYP2B2 on day 5 was similar for both culture configurations.  For 
CYP2E, collagen sandwich culture slightly outperformed the hepatocyte spheroids 
culture on day 3; however on day 5, the spheroid culture showed a 3.42 folds higher 
expression of CYP2E than in collagen sandwich.  
In addition to drug-metabolizing enzymes, various drug transporters known to 
be expressed in liver were analysed. These transporters are involved in the influx of 
endogenous substances and xenobiotics into liver, or conversely the efflux of 
endogenous substances and xenobiotics into the bile or blood [194]. Together with 
CYPs, these transporters mediate clearance of drugs from liver. Bsep, Mdr1a, and 
Mrp2 are efflux transporters which are present on the apical canalicular membrane 
[195, 196].  Oatp1 and Ntcp are located in the basolateral membrane and act as influx 
transporters. On day 3 and 5 in culture, we observed a modest upregulation of Mrp2 
in the hepatocyte spheroids at 2.6 folds and 1.7 fold, respectively (figure 18 lower 
panel). On day 3, Oatp1 had similar expression in hepatocytes cultured in both culture 
configurations. On day 5, however, there was a drastic upregulation (13 folds) in the 
sponge culture. Mdr1a expressions for both culture configurations were similar for 
both days 3 and 5.  For both Ntcp and Bsep expression on both day 3 and day 5, 





Figure 18. Gene expression of CYP450s enzymes and drug transporters. Data are 
average ± standard error of the mean from 4 independent experiments 
 
For all three cytochrome P450s in the drug induction experiments, the basal 
levels in the sponge-cultured hepatocyte spheroids showed relatively higher 
metabolite production than the collagen sandwich (figures 19A-C).  This reflected an 
improved ability of hepatocyte spheroids in metabolizing drugs and correlated with 
the upregulation of drug-metabolizing enzyme expression in hepatocyte spheroids at 
basal level (figure 18 upper panel).  Metabolite production CYP1A2 induced 
hepatocyte spheroids showed a higher absolute amount than the hepatocytes in 
collagen sandwich, 4,973 ± 1327 ng/million cells per 2 hours and 1,449 ± 173 
ng/million cells per 2 hours, respectively, as well as a higher fold of metabolite 
production activity between induced and basal levels, 18.67 folds for spheroids versus 
6.66 folds for collagen sandwich (figure 19A). For CYP2B2 induction, induced 
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hepatocyte spheroids and collagen sandwich exhibited an absolute value of metabolite 
production of 73.91 ± 1.90 ng/million cells per 2 hours and 43.96 ± 7.18 ng/million 
cells per 2 hours, respectively, but reflecting a similar 4.53 and 4.64 folds change over 
basal levels in both culture configurations (figure 19B). For CYP3A2 induction, the 
absolute value of metabolite production of the induced spheroids culture showed a 
lower value than collagen sandwich culture, 139.85 ± 9.14 ng/million cells per 2 
hours and 541.38 ± 132.83 ng/million cells per 2 hours, respectively (figure 19C). 
This translated into a 6.53 and 31.98 folds induction over basal levels for each of the 
culture configurations. The 6.53 folds induction of metabolic activity for CYP3A2 
over basal levels is still considered significant.  
 
Figure 19. Drug induction of a) CYP1A2, b) CYP2B2 & c) CYP3A2 (numbers on 
top of induced level bar denote fold induction activity changes. Data are average ± 





3.3.3 Cellulosic sponge has had exhibits comparable or better drug absorption 
properties compared to other frequently commonly-used hepatocyte platforms  
To be useful in drug safety testing it is important to characterize absorption of 
different classes of commonly used drugs in the sponge platform. Eight drugs with 
differing hydrophilicity and net charges were chosen. The definition of hydrophobic 
and hydrophilic drugs was determined based on drug partition coefficients (log P), 
where hydrophobic drugs have log P>>0 and hydrophilic drugs have P   0. For 
comparison, drug absorption experiment was performed with three other scaffolds for 
hepatocyte culture in vitro, i.e. collagen gel, PuraMatrix™ gel, and Reinnervate 
polystyrene scaffolds [95, 107, 197]. The drug absorption properties of two tested 
hydrophobic drugs were found to be dependent on the solubility limit of each drug 
(figure 20). Testosterone with low water solubility (23.4 µg/mL) and bulky chemical 
structure was found to be severely absorbed by all four tested scaffolds. WY14643, 
another hydrophobic drug with higher water solubility (40 µg/mL), showed 9 %, 14 %, 
24% and 0% drug absorption to the HA Gal sponge, collagen gel, PuraMatrix™ gel 
and Reinnervate scaffold, respectively.  For the hydrophilic drugs with positive and 
negative charges, HA Gal sponge absorbed at most 10 % of the tested drugs, which 
was less than the collagen gel and PuraMatrix™ gel but more than Reinnervate 
scaffold. Hydrophilic drugs with neutral net charges such as nicotine and caffeine 
were 29 % and 19 % absorbed in the HA Gal sponge, respectively. This was 
comparable to the extent of adsorption by collagen gels, 23% and 29%, respectively. 
PuraMatrix™ gel absorbed 45% and 32% of nicotine and caffeine, respectively. 
Reinnervate scaffold absorbed 5% and 11% of nicotine and caffeine, respectively. 
The significant absorption of hydrophilic drugs with neutral net charges to the sponge 
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correlated with the net neutral charge of the sponge (shown by its Zeta potential in 
figure 9C). In most of the tested drugs for drug absorption, the HA Gal sponge 
outperformed the collagen sandwich, which is the commonly used biomatrix for 
hepatocyte culture.  
 
Figure 20. Drug absorption properties of cellulosic sponge compared to other 
commercial cell culture platforms. Data are average ± standard error of the mean from 
3 independent experiments. 
 
3.4 Discussion 
We have conjugated galactose ligands onto cellulosic sponges by using D-(+)-
galactosamine, which is commercially available, more cost effective and readily 
useful for large-scale synthesis than customized 1-O-(6-aminohexyl)-D-
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galactopyranoside (AHG), which has been used previously [34, 86, 175]. The absence 
of a hexyl spacer in galactosamine compared to AHG was found only critical in the 
early stage of cell attachment kinetics, as shown by the comparison of HepG2 cells 
adhesion energy on the polyethylene membrane conjugated with AHG and lactobionic 
acid [198]. Unlike other hydrogels, the macroporous networks in our cellulosic 
sponge support the in situ formation and maintenance of polarized hepatocyte 
spheroids in the diffusible porosity dimension [33, 199, 200]. The cellulosic sponge, 
which acts as a hepatocyte substratum anchor, did not prevent cell aggregation, as 
would normally happen in cell culture platforms with excessive extracellular matrix 
presentation [201]. In addition, galactose presented chemical cues to the hepatocytes 
to reorganize into 3D spheroids, while the macroporous structure constrained and 
tethered them physically.  Since the galactose ligand only interacts weakly with 
ASGPR receptors in the hepatocyte cell membrane [175], it is the combination of the 
physical and chemical cues in the sponge which is important in establishing stable 
constrained hepatocyte spheroids.   
Cellulosic sponges were fabricated in large-scale with thin dimensions to reduce 
drug absorption. Compared to other scaffolds used for cultivation of hepatocyte 
spheroids, our sponge has a lower mechanical stiffness (E<10 kPa) [107, 202], 
durable macroporosity and is fabricated without chemical cross-linkers, yet cross-
linked through stable chemical bonds [15]. The soft stiffness of the sponge will 
prevent cell spreading, which is important for maintenance of the mature hepatocyte 
phenotypes [181].   
Hepatocytes cultured as 3D spheroids in the cellulosic sponge were tethered 
onto the sponge surface, which has sub-micron features, and constrained within the 
69	  
	  
macroporosity of the sponge. Hepatocyte spheroids started to form at 7 hours post-
seeding with a gradual increase in cell boundary tightness. They exhibited 
maintenance of cell viability for 7 days in culture, polarity markers and 3D cell 
morphology including a cortical F-actin cytoskeleton and tight cell-cell adhesions.  At 
16 hours post-seeding they have excreted fluorescein dyes into bile canaliculi-like 
structures, which was faster than the other platforms used to form hepatocyte 
spheroids or collagen sandwich cultures [176, 191, 203]. These translated into high 
level of albumin secretion and urea synthesis, which were significantly higher than 
collagen sandwich culture. Compared to other galactosylated scaffolds used for 
culturing primary rat hepatocytes, hepatocytes cultured in cellulosic sponges also 
showed relatively higher maintenance of albumin secretion and urea synthesis at least 
two fold [24, 60, 204]. Hepatocyte spheroids constrained in the sponge expressed 
multiple phase 1 CYP450 enzymes and drug transporters at the same or higher level 
than hepatocytes cultured in collagen sandwich with the exception of Ntcp and Bsep.   
When these spheroids were incubated with known P450 inducers such as β-
naphthoflavone (CYP1A2), phenobarbital (CYP2B2), or pregnenolone-16α-
carbonitrile (CYP3A2), the absolute value of metabolite production of CYP1A2, 
CYP2B2 and CYP3A2 were elevated, respectively. Levels of drug metabolites under 
basal conditions, as measured by LC/MS, in the hepatocyte spheroids cultured in the 
sponge were higher compared to the collagen sandwich (fig 19A-C). Upon drug 
inductions, the amount of metabolites increased even more in the hepatocytes cultured 
in HA Gal sponge, while only true for CYP1A2 and CYP2B2, the major CYPs in rat 
hepatocytes [205-207]. Similar induction folds of CYP2B2 in sponge and collagen 
sandwich culture were correlated to the reduction of CYP2B2 expression in 
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hepatocyte spheroids between day 3 to day 5 to a similar level with the collagen 
sandwich culture on day 5 (figure 18 upper panel).  CYP3A2 showed lower but still 
significant level of induction. The sponge exhibited lower or comparable drugs 
absorbency than collagen gel, Puramatrix™ gel and Reinnervate scaffold. Overall, the 
galactosylated cellulosic sponge supports the uniform formation, maintenance and 
functions of hepatocyte spheroids that are useful for drug safety testing. 
 
3.5 Conclusion 
We have synthesized and fabricated a galactosylated macroporous cellulosic 
hydrogel sponge as a platform to culture hepatocytes as 3D spheroids for drug safety 
testing applications. The soft and diffusible dimension macroporous cellulosic sponge 
with conjugated galactose facilitates the formation of hepatocyte spheroids by 
presenting both the mechanical cues (via matrix rigidity) and chemical cues for the 
hepatocytes to reorganise into 3D spheroids within 7 hours post-seeding. The 
constrained hepatocyte spheroids maintain cell viability, cell polarity markers, and 3D 
cell morphology. These translate into maintained hepatocyte-specific functions and 
expression of drug metabolic enzymes and drug transporters. Furthermore, hepatocyte 
spheroids grown in the sponge show inducibility of various drug metabolizing 
enzymes including CYP1A2, CYP2B2 and CYP3A1. The sponge has comparable or 
lower drug absorbency as other cell culture scaffolds. Importantly, sponge fabrication 
is amenable for large-scale production and high-throughput screening. Cell seeding 
into the sponge involves simple steps similar to high-throughput 2D cell cultures. 
Together, this platform provides a promising tool for hepatocyte-based drug safety 
testing. As other cells such as stem cells, neuroblasts and cardiomyocytes also show 
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more mature phenotypes when cultured as spheroids, cellulosic sponges may have 




















 CHAPTER 4 
GALACTOSYLATED CELLULOSIC SPONGE AS PLATFORM TO STUDY 
HCV INFECTION 
4.1 Introduction 
Hepatitis C virus (HCV) has currently infected 130-200 million human 
populations in the world, with 3-4 million new cases reported annually [208]. This 
flaviviridae family virus can lead to chronic hepatitis, cirrhosis then eventually 
hepatocellular carcinoma [114]. One of the most commonly found HCV strains is 
genotype 1 (~70%) [209]. The ribonucleic acid (RNA) of the virus encodes 3,000 
amino acid length-single polyprotein, which upon infecting the host, structural and 
non-structural proteins are formed [121]. Therefore, anti viral candidates has been 
developed to target these proteins. The only currently available registered choice to 
treat HCV infection is by administering ribavirin and PEG interferon 2α, which could 
lead to side-effects such as	  harsh, flu-like symptoms, anaemia and depression [113]. 
Worse, upon drug administration the patient became too weak to work or enjoy family 
life, and the virus often manages to survive under these conditions [113]. Moreover, 
PEG interferon 2 α and ribavirin are only effective against genotype 2 HCV [210]. 
Patients with genotype 1 had the lowest drug response levels (42-46% for PEG 
interferon 2 α plus ribavirin in the two trials) and patients with genotype 2 or 3 had 
the highest levels of drug response response (76-82% for PEG interferon 2 plus 
ribavirin in the two trials) [211]. 
The host specificity of HCV in human and chimpanzee liver has challenged the 
study to be done in vitro to observe how virus enters the cells and infect the hosts 
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[212]. Recent developments to propagate HCV in human hepatoma cell lines have 
shown some features but these cell lines, however, display abnormal proliferation, 
peculiar gene expression, as well as deregulated signaling and endocytic functions 
[213-216]. Primary human hepatocytes are considered the most physiologically 
relevant cells to study HCV infection and replication in vitro, but they are difficult to 
handle upon isolation from in vivo environment; the cells viability and functions 
started to drop if not preserved or cultured properly [217]. Currently there are not 
many robust in vitro 3D models to culture human hepatocytes to maintain the cells 
polarity for prolonged culture to let the HCV stains keep re-infecting the host cells. 
iPS-derived human hepatocytes can also be used to study HCV entry and infections in 
vitro but are normally specific to fetal hepatocyte [165]. Researchers have performed 
several strategies to culture primary human hepatocytes by manipulating extracellular 
matrix, formulating proper cell culture media composition, culturing the cells using 
bioreactors, co-culturing with non-parenchymal cell and culturing hepatocytes by 
enhancing cell-cell interactions through 3D spheroids formation [92, 94, 151, 217]. 
However, until now it is still unclear whether these platforms could support HCV 
glycoprotein mediated entry and persistent replication in vitro.  
Previously, we have shown that our galactosylated cellulosic sponge platform 
has salient features such as rapid formation of spheroids, facilitates homotypic 
interaction, controlled spheroids dimensions, easily scalable multi-well format and 
mechanical properties suitable for soft tissue culture. Therefore we hypothesized that 
this could preserve difficult-to-culture human hepatocytes by presenting mechanical 
and chemical cues to be polarized cells. Rapid hepatocyte spheroids formation (within 
7 hours) could help in restoring hepatocyte functions. This thin sponge to be used as 
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HCV infection study platform also offers its capability towards large scale antiviral 
screening.   
Here we demonstrated the utility of our thin macroporous galactosylated 
cellulosic sponge (1 mm thickness, 6 mm diameter) to culture cryopreserved primary 
human hepatocytes and Huh 7.5 cells as spheroids in a multi-well plate to support 
HCV infection.  Both human hepatocytes and Huh 7.5 cells formed compact 
spheroids within 1 day post-seeding and maintained their tight spheroid configuration 
over prolonged culture of up to 40 and 21 days, respectively. These spheroids 
maintained good cell viability, expressed polarity markers (MRP2 and CD147) and 
displayed HCV entry markers such as CD81, SCARB1 and Claudin1. Upon 
incubation with HCV pseudoparticles (HCVpp), these spheroids showed high level of 
infectivity with no visible mass transfer barrier. Dose-dependent response of HCV 
entry inhibition was also observed upon co-incubating HCVpp with CD81 antibody. 
Overall, this platform is useful to culture primary human hepatocyte and hepatocyte 
cell line to study HCV infection and to screen HCV antiviral candidate.  
 
4.2 Materials and methods 
4.2.1 Materials 
All chemicals and reagents were purchased from Sigma Aldrich (Singapore), 




4.2.2 Synthesis and fabrication of galactosylated cellulosic sponge (HA Gal 
sponge) 
The detail synthesis has been described previously in chapter 3 and in [80]. 
Hydroxypropyl cellulose (HPC), Mw = 80,000 g/mol and ~3.4 degree of 
etherification was dehydrated by azeotropic distillation in toluene at 70°C. 4 grams of 
dried HPC was dissolved in anhydrous chloroform (100 mL), to which 2.095 mL allyl 
isocyanate 98% and 1 mL dibutyltin dilaurate 95% were added dropwise. The mixture 
was stirred vigorously for 48 hours at room temperature, after which it was 
precipitated in an excess amount of anhydrous diethyl ether.  Following vacuum 
drying, the product was dissolved in deionized water (DI H2O), purified by dialysis 
for 3 days, and finally lyophilized to the intermediate product, HA. For galactose 
conjugation, 1 gram of HA was dissolved in 15 mL anhydrous dimethyl formamide 
(DMF) in which the hydroxyl groups were activated by addition of 1,1’-
carbonyldiimidazole (0.322 g in 2 mL DMF).  D-(+)-galactosamine HCl (0.427 g in 
30 mL DMF), which was dissolved with addition of triethylamine, was added to the 
mixture with two folds molar ratio compared to D-(+)-galactosamine HCl. The 
reaction was carried out for a further 48 hours at room temperature. To remove 
impurities, the mixture was further dialyzed in excess methanol and subsequently in 
deionised water for 3 days each and the final product (HA Gal) was lyophilized.   
HA Gal was dissolved in deionised water to a final concentration of 10 % 
wt/vol after which the solution was inserted into tubes (diameter 6 mm, length 3 cm). 
The tubes were heated in a water bath (40°C) until phase separation occurred, and 
then crosslinked by γ irradiation for 1 hour at a dose of 10 kGray/hour (Gammacell 
220, MDS Nordion, Canada). The sponge monoliths were obtained by breaking tubes 
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subsequent to freezing in dry ice. A Krumdieck tissue slicer (Alabama Research & 
Development USA) was used to cut the sponge uniformly (40 rpm for 1 mm 
thickness). Thin sponge slices were fabricated to reduce possible anti viral absorption 
during assays. Sliced sponges were washed extensively with excess amounts of 
deionised water for 3 days to remove uncross-linked polymers. Finally, slices were 
lyophilized and sterilized by γ irradiation prior to cell seeding.   
 
4.2.3 Cell culture 
4.2.3.1 Cryopreserved primary human hepatocyte culture 
Primary human hepatocytes were maintained in Williams’ E media 
supplemented with human hepatocyte maintenance supplements from Invitrogen 
containing dexamethasone, penicillin streptomycin, insulin, transferrin, selenium 
complex, bovine serum albumin (BSA), linoleic acid, GlutaMAX and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). 0.1 millions human 
hepatocytes were seeded into each HA Gal sponge (6 mm diameter, 1 mm thickness) 
in total 16 µL culture medium. Fresh culture medium was added to the sponge edge 
after 30 minutes incubation (300 µL per sponge in 48-well plate).  
4.2.3.2 Huh 7.5 cell culture 
Aside from primary human hepatocytes, as a known control for the HCV 
infection study, we also cultured Huh 7.5 cells in the sponge. Previous research 
findings have shown that Huh 7.5 cells were highly permissive to HCV infection and 
replication [218]. Huh 7.5 cells were propagated in DMEM (high glucose) media 
supplemented  with 1x minimal essential amino acids and 10% FBS. Cells were 
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passaged at 80% confluence. 0.1 millions Huh 7.5 cells were seeded into each HA Gal 
sponge (6 mm diameter, 1 mm thickness) in total 16 µL culture medium. Fresh culture 
medium was added to the sponge edge after 30 minutes incubation (300 µL per 
sponge in 48-well plate).  
 
4.2.4 Human hepatocyte and Huh 7.5 spheroids characterizations and functional 
assessments 
4.2.4.1 Spheroids size distribution 
Spheroid size distribution was quantified using imageJ software (version 1.43u) 
from collective phase contrast images of living human hepatocyte and Huh 7.5 
spheroids cultured in the HA Gal sponges on day 3 (week 0), day 7 (week 1), and day 
14 (week 2).  
4.2.4.2 Live/dead staining 
Human hepatocyte and Huh 7.5 spheroids were co-stained with Cell Tracker 
Green (CTG, 20 µM) (Molecular Probes, USA) and propidium iodide (PI, 25 µg/mL) 
(Molecular Probes, USA) to determine live and dead cells, respectively. Cells were 
incubated for 30 min at 37°C and then fixed with 3.7 % paraformaldehyde for 10 min 
at room temperature. Fluorsave (Merck Chemicals) was applied to the stained 
spheroids to minimize photo-bleaching. Images were acquired by confocal laser 





4.2.4.3 Scanning electron microscopy  
Hepatocyte spheroids in sponges were fixed with 3.7% paraformaldehyde 
overnight and stained with 1% OsO4 for 1 hour. Samples were then dehydrated step-
wise with ethanol (25%, 50%, 75%, 90% and 100%) for 10 min each, dried in a 37°C 
dry oven and sputter-coated with platinum for 90 seconds. The samples were viewed 
with a scanning electron microscope (JEOL JSM-5600, Japan) at 10 kV. 
4.2.4.4 Reverse transcriptase polymerase chain reaction  
RNA was extracted from hepatocytes cultured as 3D spheroids in HPCSS Gal 
sponges by RLT lysis buffer (Qiagen, Singapore). Total RNA concentration was 
quantified by a Nanodrop (Thermoscientific) and 1 µg of RNA was converted to 
cDNA by High Capacity RNA-to-cDNA (Applied Biosystems). Primers were 
designed using Primer 3 and real-time PCR was performed by using SYBR green fast 
master mix on a ABI 7500 Fast Real-Time PCR system (Applied Biosystems). Gene 
expression was calculated using the ΔΔCT method normalized to GAPDH. The 
primers used in experiment are shown below.  
Table 5. Primer sequences used in RT-PCR experiments 











































AAT: α-1-antitrypsin, CYP: Cytochrome P450, HNF4α: Hepatocyte Nuclear Factor 
4α  
P.S.: Product size, Annealing temperature: 60°C, Cycle numbers: 40 
4.2.4.5 Immunofluorescence microscopy of spheroids 
Cells were fixed with 3.7% paraformaldehyde for 10 minutes followed by 
washing with PBS.  Following washing and blocking with 2% BSA/0.2% Triton-X 
100, the spheroids were incubated overnight at 4°C with primary antibodies: mouse 
anti-human CD81 (clone JS-81, BD Pharmingen; 1:100), rabbit anti-SCARB1 
(NB110-57591, Novus Biologicals; 1:100), rabbit anti-Claudin1 (51-9000, Zymed; 
1:100), rabbit anti-MRP2 (Clone M2III-6, Sigma Aldrich; 1:50) and rabbit anti-firefly 
luciferase (AbCam, 1:100). Secondary antibodies used were goat anti-mouse and goat 
anti-rabbit 488 and 555, respectively. Nuclei stain was captured using mounting 
medium containing DAPI stain (Vecta Shield). Images were captured using Olympus 
fluoview FV1000 with a 60x water lens. Images were analysed using IMARIS and 
images assembled using Adobe illustrator CS2.  
 
4.2.5 HCV pseudoparticles (HCVpp) synthesis 
The HCVpp were synthesized at Roche Nutley Virology Department, USA by 
co-transfection of plasmids encoding E1 and E2 HCV glycoproteins, HIV lacking nef 
and env genes and containing luciferase gene into 293T cells.  
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4.2.6 HCVpp entry and inhibition assays 
Human hepatocytes and Huh 7.5 spheroids were cultured for 3 days post-
seeding before proceeded into HCVpp entry experiments. These spheroids were 
subjected to treatment with 100 µL of media containing 2% DMSO and 2x penicillin 
streptomycin containing antiviral drugs at various concentrations.  To this media 50 
µL of HCVpp solution was added. The spheroids were incubated for 3 days. End 
points of viral entry were measured post infection by immunofluorescence staining 
and luciferase assay measuring total luminescence using Promega Steady Glo kit. 
Additionally, the infection experiments were performed in human hepatocyte 
spheroids on day 10 and 14 post-seeding to observe prolonged infection.  
 
4.2.7 Statistical analysis 
Statistical comparisons were undertaken using paired two-tailed Student’s t tests. 
Results are expressed as mean ± standard deviation. Confidence interval to be 









4.3 Results  
4.3.1 Characterization of the human hepatocyte and Huh 7.5 spheroids cultured 
in cellulosic sponges  
4.3.1.1 Human hepatocyte and Huh 7.5 spheroids are formed in galactosylated 
cellulosic sponge and maintained for over 2 weeks of culture 
We first analysed the ability of galactosylated cellulosic sponge in inducing 
human hepatocytes and Huh 7.5 cells to form spheroids and we found that the cells 
formed spheroids within the first 24 hours post-seeding (figure 21).  Both human 
hepatocytes and Huh 7.5 cells formed tight spheroids within 3 days post-seeding and 
maintained their spheroid configuration over prolonged culture of up to 40 days and 
21 days, respectively.  
Figure 21. Phase contrast images of human hepatocyte spheroids (upper panel) and 




We characterized the size distribution of human hepatocyte and Huh 7.5 
spheroids in culture and we found that most human hepatocyte spheroids formed were 
between 50-80 µm in size (~45%) from day 3 until Day 14 in culture (figure 22). 
Whereas, due to proliferative nature of Huh 7.5 cells, most Huh 7.5 spheroids were 
between 80-120 µm in size (~ 63%) on day 3 of culture and there was an increase in 
number of spheroids between 150-200 µm in diameter over 14 days in culture (~27% 
increase) (figure 22). 
 
Figure 22. Human hepatocyte and Huh 7.5 spheroids size analysis and distributions. 
Data are average ± standard deviation (n = 11) 
 
We further determined the viability of the spheroids for both cell types over 40 
days of culture and found that human hepatocytes remained highly viable (~80% 
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viability) in spheroids over 40 days in culture while the Huh 7.5 spheroids lost most 
of their viability after 3 weeks in culture which could be due to hypoxia in the centre 




Figure 23. Live/dead staining of human hepatocyte and Huh 7.5 spheroids (projected 
spheroids images, scale bar 15 µm) 
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 SEM images of both cell types’ spheroids portrayed tight spheroids formation 
and maintenance of the spheroids compact morphology over prolonged culture; 6 
weeks for human hepatocytes and 3 weeks for Huh 7.5 spheroids (figure 24).  
Interestingly, SEM images of human hepatocyte spheroids showed 1-2 µm size holes 
on the spheroid surface of the spheroids (see the arrows) which was reported before to 
be bile canaliculi-like structures extending from the surface to the interior of the [219]. 
These holes also commonly appear in mammalian liver (figure 25).   
 
 






Figure 25. a) High magnification SEM images of human hepatocytes spheroids at 
different weeks of culture and b) Mammalian liver SEM image adapted from [220]. 
Scale bar 1 µm 
 
4.3.1.2 Human hepatocyte and Huh 7.5 spheroids maintain polarized phenotypes 
and express HCV entry markers 
Phenotypic differentiations of the two kinds of spheroids were assessed by 
analyzing liver specific genes over 14 days of culture. Primary human hepatocytes 
cultured as spheroids exhibited minimal dedifferentiation compared to freshly thawed 
cryopreserved human hepatocytes for various lots (figure 26A). Mature human 
hepatocyte genes like CYP1A1, CYP3A4, HFN4α and Albumin were upregulated in 
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the spheroid culture at 1,024, 4, 5,700 and 90 folds, respectively. AAT gene was 45 
folds downregulated. For Huh 7.5 spheroids, we observed a significant increase in the 
transcript levels of CYP3A4 and Albumin genes (256 and 16,384 folds, respectively 
after 7 days of culture) (figure 26B). These important mature hepatocyte genes 
showed significant increase over 7 days of culture and maintained similar levels of 
expression until 14 days in culture. The other genes like AAT, CYP1A1 and HNF4α 
were maintained from day 1 to day 14 of culture.  
 
Figure 26. Gene expression analysis of human hepatocyte and Huh 7.5 spheroids. 
Data are average ± standard deviation of 3 independent experiments. 
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Hepatocyte polarity was found to significantly contribute to HCV entry [4]. And 
it has been discussed in chapter 2 that HCV enters hepatocytes via binding with 
various receptors [110]. We characterized the expression and localization of these 
markers and receptors in our spheroid cultured cells by immunofluorescence staining.  
Hepatocyte polarity markers such as MRP2 and CD147 were visualized at the tight 
junctions and at the basolateral domain, respectively (figure 27).  
 
Figure 27. Liver polarity markers of human hepatocyte and Huh 7.5 spheroids (2 µm 




Various HCV entry markers namely CD81, SCARB1 and Claudin1 were also 
characterized in the spheroids. CD81 was visualized at the basolateral domain of the 
cells. SCARB1 and Claudin1 were visualized at the tight junction regions of the 
spheroid (figure 28).  We observed these markers expression in the spheroids over 
extended culture of up to 14 days.    
 
Figure 28. HCV entry markers stained in human hepatocyte and Huh 7.5 spheroids (2 
µm thickness slice image of spheroid core, scale bar 20 µm)  
 
4.3.2 HCV infection susceptibility study of the spheroids 
4.3.2.1 Human hepatocyte and Huh 7.5 spheroids are susceptible to HCV 
infection demonstrated through HCV pseudoparticles 
In order to further test the susceptibility of our human hepatocytes and Huh 7.5 
spheroids system to glycoprotein-mediated HCV entry, we inoculated the spheroids 
with HCV pseudoparticles (HCVpp).  HCVpp were the first available in vitro 
infection model for investigation of the entry of this major human pathogen [221]. We 
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found high levels of infectivity in both human hepatocytes and Huh 7.5 spheroids. 
The levels of infectivity was found to be much higher than the previously reported 3D 
culture model; ~80% of the spheroids were infected compared to just 1% cells 
infectivity in previously reported HCV culture model [3]. The cells at the centre of the 
spheroid were also infected with pseudoparticles indicated by the luciferase staining, 
which showed that this spheroid system is not subjected to mass transfer limitation at 
the spheroid core (figure 29). The ability of human hepatocyte spheroids to support 
HCVpp entry at prolonged culture (day 3, day 10 and day 14 post-seeding) further 
substantiated the findings that the HCV entry receptors were present and localized in 
the spheroids over prolonged culture periods (figure 30).  
 
Figure 29. Immunofluorescence of HCVpp-infected human hepatocyte and Huh 7.5 






Figure 30. HCVpp entry in human hepatocyte spheroids in prolonged culture 
(projected spheroid images, scale bar 20 µm). N.S.: not significantly different 
 
4.3.2.2 The entry of HCV pseudoparticles into human hepatocyte and Huh 7.5 
spheroids can be inhibited by JS-81 in dose-dependent manner 
To demonstrate the utility of our spheroids model to screen antiviral compound 
we co-incubated HCVpp with CD81 antibody. CD81 antibody was reported 
previously to inhibit HCV entry by reducing the availability of CD81 receptors to 
mediate HCV entry [222]. The presence of CD81 antibody inhibited HCVpp entry in 
a dose dependent manner (figure 31). The CD81 antibody concentration when 50% of 
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HCVpp entry was inhibited, labelled as IC50, was estimated to be 500 ng/mL for 
human hepatocytes and 100 ng/mL for Huh 7.5 cells (figure 31 left and right panel, 
respectively). These IC50 values were close to the previously reported values i.e. < 1 
µg/mL [118].  
	   
Figure  31. Inhibition assay of HCVpp entry in human hepatocyte and Huh 7.5 




We have demonstrated the utility of our galactosylated cellulosic sponge (HA 
Gal sponge) to culture human hepatocyte and Huh 7.5 cells as 3D spheroids in multi-
well format for HCV infection (entry and inhibition) study. Within 24 hours post-
seeding, both types of cells had reorganized to form compact spheroids morphology. 
Galactose conjugated on the sponge presented chemical cues to the cells to reorganize 
into 3D spheroids, while the macroporous structure constrained them physically. 
Since galactose ligand only interacts weakly with ASGPR receptors in the hepatocyte 
cell membrane, it is the combination of the physical and chemical cues in the sponge 




Human hepatocyte spheroids size was maintained at the size of mass transfer barrier-
free (majority size 50-80 µm) while proliferative Huh 7.5 spheroids reached 150-200 
µm range. Spheroid viability of human hepatocyte spheroids maintained at least up to 
5 weeks of culture however Huh 7.5 spheroids viability decreased significantly 
beyond 3 weeks of culture due to the increase in spheroids size limiting the mass 
transfer into the spheroids core. The spheroids morphology observed by SEM 
revealed tight spheroids morphology of these two types of spheroids and their 
maintenance over prolonged culture; 6 weeks and 3 weeks for human hepatocytes and 
Huh 7.5 spheroids, repectively. Human hepatocyte spheroids exhibited additional 
spheroids feature observed at higher magnification that is the 1-2 µm size hole located 
on spheroids surface which was reported before to be bile canaliculi-like structures 
extending from the surface to the interior of the spheroid  [219].  
Spheroids morphology correlated well with the expression of various mature 
differentiated hepatocyte genes being upregulated and or maintained over prolonged 
culture. Human hepatocytes spheroids exhibited minimal dedifferentiation compared 
to freshly thawed cryopreserved human hepatocytes. Mature human hepatocyte genes 
like CYP1A1, CYP3A4, HFN4α and Albumin were upregulated in the spheroid 
culture at 1,024, 4, 5,700 and 90 folds, respectively. For Huh 7.5 spheroids, we 
observed a significant increase in transcript levels of CYP3A4 & Albumin genes (256 
and 16384 folds, respectively after 7 days of culture). These important mature 
hepatocyte genes were further maintained at similar levels of expression until 14 days 
in culture. The other genes like AAT, CYP1A1 and HNF4α were maintained from 
day 1 to day 14 of culture. 
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Both human hepatocyte and Huh 7.5 spheroids displayed hepatocyte polarity 
markers such as MRP2 and CD147 (visualized at the tight junctions and at the 
basolateral domain, respectively). Hepatocyte polarity markers were previously 
reported to be one of the requirements for HCV entry and propagation [4]. These 
spheroids also showed HCV entry markers namely CD81, SCARB1 and Claudin1. 
These HCV markers were reported to be important in the early phase of HCV 
infection [110]. CD81 was visualized at the basolateral domain of the cells while 
SCARB1 and Claudin1 were expressed at the tight junction regions of the spheroid.  
We observed these markers expression in the spheroids over extended culture of up to 
14 days.  
When these spheroids were inoculated with HCVpp to study the HCV entry, 
they exhibited high infection level throughout the whole spheroid region (~80% of 
total spheroids were infected). This infection level was significantly higher compared 
to other previously reported model to study HCV entry in human hepatocyte [118].  
These spheroids cultured in the thin sponge were amenable to be inoculated with 
HCVpp in 96-well plate format, which brings the high throughput feature of our 
system. Importantly for human hepatocyte spheroids, HCVpp were able to infect the 
spheroids on a prolonged culture which secures our hypothesis for further 
investigation in HCV replication study. When both types of spheroids were co-
incubated with HCVpp with CD81 antibody, we observed a dose-dependent inhibition 
of the HCV infection. 50% of HCVpp entry was inhibited by CD81 antibody at 
concentration of ~500 ng/mL for human hepatocytes and ~100 ng/mL for Huh 7.5 





We have elucidated the usefulness of our galactosylated cellulosic sponge for 
human hepatocyte and Huh 7.5 cell 3D culture as spheroids for multi-well HCV entry 
and inhibition study. Human hepatocyte and Huh 7.5 spheroids are formed in the 
sponge within 24 hours post-seeding and constrained in the sponge macroporosity for 
prolonged culture. The size of the spheroids lies within mass transfer barrier-free 
range. Spheroids viability is well maintained up to 5 and 2 weeks for human 
hepatocyte and Huh 7.5, respectively. The compact spheroids morphology is observed 
at least up to 2 weeks of culture. Compact spheroids morphology correlates well with 
gene expression showing minimal dedifferentiation of human hepatocyte spheroids 
and upregulation of mature hepatocyte genes in Huh 7.5 spheroids. Both types of 
spheroids express liver polarity markers and HCV entry markers. When these 
spheroids are inoculated with HCVpp, an available in vitro model to study HCV entry, 
~80% of the spheroids are infected with HCVpp distributed throughout whole 
spheroids region. Human hepatocyte spheroids have shown the ability to be infected 
at prolonged culture indicating the maintenance of HCV entry markers. By co-
incubating both types of spheroids with HCVpp and CD81 antibody, HCVpp entry is 
inhibited at dose-dependent manner. Together, this spheroids model provides a useful 








CLEAVABLE CELLULOSIC SPONGE DEVELOPMENT FOR 3D CELL 
CULTURE AND SPHEROIDS RETRIEVAL 
5.1 Introduction 
In tissue engineering scaffold design, it is ideal to have the scaffold to be 
biodegradable because three dimensional scaffolds serves only as temporary support 
for cell growth [223]. Upon study completion or for further downstream cell assays, 
the bulk amount of the scaffold materials need not to be present hence 
biodegradability is important. Ideally, scaffold degradation products should not elicit 
cytotoxicity or immunological responses and it is desired to have water soluble 
degradation product for easy by products removal. As shown previously, cellulosic 
sponge has shown many salient features for cell culture applications such as high 
water uptake, excellent hydrophilicity, diffusible and aqueous macroporosity, 
versatility for ligand conjugation, soft mechanical stiffness suitable for soft tissue 
culture, induces quick hepatocyte repolarization through accelerated spheroids 
formation, ease of cell seeding procedure and capability for large scale cell culture 
and drug/anti viral screenings [15, 80, 166]. Macroporous hydrogel sponge made of 
cellulose derivative could entrap cells, induce spheroids formation and maintain these 
constructs within the macroporous networks over extended culture period. However 
the current cellulosic sponge design is non-degradable during cell culture thus impose 
challenges to retrieve living spheroids from the sponge for further analysis and further 
use. Addition of trypsin or other dissociating enzymes to retrieve these spheroids is 
unable to achieve good spheroids harvesting yield. Biodegradation capability of this 
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class of novel cellulosic sponge has not been investigated. The reason is probably due 
to its rare application as tissue engineering scaffold.  
To our knowledge, others have explored a way to degrade cellulose derivative 
materials using cellulase enzyme from Aspergillus niger to hydrolyze 1,4-β-D-
glycosidic linkages  but it might not be suitable for cell culture applications involving 
sensitive cells e.g. primary hepatocyte and stem cells [224]. Our attempt has also 
proven that this enzyme did not cleave our cellulosic sponge in which γ ray-
crosslinked polymer has a rather strong covalent bond. Other class of polymeric 
scaffold such as polyester has been explored as hydrolysis induced-degradable 
scaffold but the degradation mechanism is rather slow and sometimes unpredictable 
[225]. Although the degradation occurs physiologically, they only exhibit gradual 
degradation kinetics with degradation times ranging from days to months [226]. In 
addition, this continuous hydrolysis process leads to the gradual weakening of the 
system during tissue growth. It is desirable to maintain the scaffold mechanical 
stiffness to support the cell/tissue growth throughout the culture that still allows on 
demands degradation kinetics upon completion of the study.  The possibility to attach 
UV-sensitive bond in the scaffold chemical construct is an option to make the scaffold 
degradable on demand, as it has shown robust application for cell culture, but the use 
of high power and intensity of UV to cleave the labile bond might be detrimental to 
mature and sensitive cells we are mainly using [227]. With this respect, disulfide 
bonds are of our particular interest since they are stable against hydrolysis but can be 
cleaved on demand in the presence of reducing agents.  The applications of disulfide 
bonds as cleavable bond have been investigated for various applications ranging from 
drug delivery to tissue engineering researches [228, 229]. In particular for soft tissue 
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culture, disulfide-containing scaffold was found to be suitable in 3D environment of 
in vitro tissue culture to be utilized for replacing diseased tissue in vivo [226].  
Disulfide bond cleavability has been known for years in protein synthesis 
mechanism.  When cysteine is oxidized it will form cystine, which is actually two 
cysteine residues joined by a disulfide bond (cysteine-S-S-cysteine) between the -SH 
group [230]. In recent years, there is an increasing interest to prepare scaffold 
matrices containing disulfide crosslinked bonds since cleaving these bonds is 
controllable under physiological condition by altering the concentration of reductant 
used [231-234]. Through chemical cleaving, disulfide bond (-S-S-) would readily 
decompose into thiol groups (-SH HS-). These thiol groups also do not decrease the 
local pH like what it was commonly observed in polyester hydrolysis mechanism 
[235]. Various chemical reductants are known to cleave disulfide bonds e.g. 
dithiothreitol (DTT), glutathione (GSH), L-cysteine (Cys) and tris(2-carboxyethyl) 
phosphine (TCEP) [232, 236-239]. The insertion of this disulfide bond into the 
hydrogel construct has been known to induce cleavage in physiological condition by 
incubating with reductants. Soluble decomposed products were easily removed by 
washing with excess cell culture medium or buffer [240]. Various disulfide-
containing hydrogels were already reported as temporary hydrogel template, ECM-
mimicry matrix and 3D cell encapsulation platform [223, 232, 238, 240]; however we 
found that there is still no exploration on cleavable macroporous disulfide-containing 
cellulosic sponge as hydrogel template for spheroids culture and retrieval.  
The disulfide-containing cellulosic sponge is designed to be used as 3D 
spheroids hepatocyte culture and retrieval of these spheroids. Other cell types that 
show good functionality if cultured as spheroids are also explored e.g. cancer and 
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stem cells. Therefore careful polymer design and choice of less cytotoxic reductant 
were performed. Tris(2-carboxyethyl) phosphine (TCEP), a known less cytotoxic 
chemical reductant, is used to cleave the disulfide bonds in the cellulosic macroporous 
sponge.  Compared to a known and strong chemical reductant dithiothreitol (DTT), 
TCEP is found to be more chemically stable, more effective in cleaving disulfide 
bond and able to reduce disulfide bonds at wider pH range; TCEP is effective at wider 
range of pH, 1.5-8.5, while DTT is only effective at pH 7-8.1 [241-243]. In terms of 
cytotoxicity, although 10 mg/mL TCEP was found to reduce cell viability upon 24 
hours of exposure to the cells but still in the acceptable range of 60% remaining 
viable cells [244]. In our attempt to develop disulfide-containing cellulosic sponge, 
we aim to synthesis a sponge which can be cleaved less than 1 hour thus reducing the 
exposure time between the cells and reductant.  
Here, we have demonstrated by conjugating reducible disulfide bond into 
hydroxyl groups at the side chain of hydroxypropyl cellulose prior to attaching the 
double bond for crosslinking, we can tailor the cellulosic sponge to be readily 
cleavable on-demand upon addition of suitable disulphide bond reductant that works 
best under a range of cell-compatible conditions. The sponge cleavage occurs at 
physiological condition (pH 7.4, 37°C, in cell culture medium and or buffer) within 
30 minutes without inducing significant cell toxicity, disruption of cell-cell adhesions, 
primary hepatocyte polarity markers and cytochrome P450 enzymes. The insertion of 
disulfide bond at the side chain of hydroxypropyl cellulose also does not interfere 
with the formation of macroporous network of cellulosic sponge as well as the 
crosslinkability of the hydrogel with γ irradiation. Moreover this modification does 
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not inhibit the ligand conjugation process onto the sponge for subsequent cell culture 
application.  
Comparing our disulfide-containing cellulosic sponge to the other disulfide-
containing hydrogel systems, our technology shows the importance of having 
macroporous networks with mechanically and chemically tunable properties of the 
sponge for 3D cell culture within diffusible construct rather than cell encapsulated in 
hydrogel system. The presence of macroporous networks is hypothesized to accelerate 
the sponge cleavage. Sponge macroporosity helps in the formation of cell-dense 
construct i.e. spheroids. Our disulfide-containing sponge also shows significantly 
faster cleavage rate at the addition of comparable reductants concentration than other 
disulfide-containing hydrogels (which cannot form spheroids as in our sponge likely 
due to blockage of cell-cell interactions by hydrogels) i.e. spheroids can be easily 
retrieved from our sponge as fast as 30 minutes [223, 240]. Compared with the prior 
art of cellulosic sponge [15], this cleavable disulfide-containing cellulosic sponge has 
been designed and synthesized with novel chemistry that is not obvious. The 
reduction condition importance for cytocompatibility with rapid sponge cleavage for 
intended applications with utilities have been explored and experimentally determined.  
 
5.2 Materials and methods 
5.2.1. Materials 
All chemicals and reagents were purchased from Sigma Aldrich (Singapore), 
unless otherwise stated.  
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5.2.2 Chemical synthesis of disulfide-containing hydroxypropyl cellulose polymer 
(HPCSS) 
Hydroxypropyl cellulose (HPC) Mw = 80,000 g/mol and degree of 
etherification ~3.4 was dehydrated by azeotropic distillation in toluene at 70°C. The 
chemical synthesis consists of 2 steps. The first step of the reaction was inspired by 
the Steglich esterification reaction with 4-dimethylaminopyridine (DMAP) as the 
catalyst to conjugate carboxylic group into alcohol group [245].  1 gram of dried HPC 
was dissolved in 30 mL anhydrous dimethylformamide (DMF), to which 5.95 mmol 
of DMAP was added. In a separate flask, 5.95 mmol of dithiodipropionic acid (DTDP) 
was dissolved in 30 mL anhydrous DMF. Completely dissolved DTDP was activated 
with 2.98 mmol of each 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 
N-hydroxy succinimide (NHS) for 10 minute. The activated DTDP solution was 
added to HPC/DMAP mixture and reacted for 24 hours at room temperature under N2 
blanket. The mixture was then dialyzed in excess methanol and water, subsequently, 
and lyophilized. The end product is denoted as HPCDTP. 
The second step of the reaction is an esterification reaction to conjugate amino 
group into carboxylic group. HPCDTP was dissolved in 30 mL deionized water and 
activated with two molar ratio of each EDC and N-hydroxysulfosuccinimide (sulfo-
NHS) for 10 minute. In a separate flask, two molar ratio of 2-amino ethyl 
methacrylate hydrochloride was dissolved in 30 mL deionized water. 2-amino ethyl 
methacrylate hydrochloride solution was added to the activated HPCDTP mixture and 
reacted for 24 hours at room temperature under N2 blanket. The mixture was then 
dialyzed in excess water subsequently and lyophilized. The end product is denoted as 
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HPCSS. A schematic diagram with the complete synthesis described, including 1H 
NMR characterization are shown in figures 32 and 33. 
 
5.2.3 Preparation of HPCSS sponges 
Firstly, HPCSS was dissolved in deionised water to a final concentration of 
10% wt/vol after which the solution was inserted into glass tubes (diameter 10 mm, 
length 6 cm). The tubes were heated in a 40°C water bath until phase separation 
occurred and then crosslinked by γ irradiation for 1 hour at a dose of 10 kGray/hour 
(Gammacell 220, MDS Nordion, Canada). The sponge monoliths were obtained by 
breaking tubes subsequent to freezing the frozen glass tubes in dry ice. A Krumdieck 
tissue slicer (Alabama Research & Development USA) with set speed 50 rpm was 
used to cut the sponge uniformly. Sliced sponges were further washed extensively 
with excess amounts of deionised water for 3 days to remove uncross-linked polymers. 
These sponges were lyophilized prior to further galactosylation.  
 
5.2.4 Galactosylation of HPCSS sponges (HPCSS Gal sponges) 
The lyophilized pre-sliced HPCSS sponge was immersed in acetone three times 
within 20 min interval each (1 mL of acetone per 10 mm diameter 1 mm thickness 
sponge). The sponge was further activated with 2 mM 1,1’-carbonyldiimidazole (CDI) 
dissolved in acetone for 30 min and shaken at 4°C. The activated sponge was washed 
with acetone three times to remove the excess CDI. 2 mg/ml of D-(+)-galactosamine 
dissolved in carbonate bicarbonate buffer pH 10 was added and reacted at 4°C for 24 
hour. This concentration of added galactose was found to be the optimum in the 
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chemical synthesis. The reacted sponge was subsequently washed with excess of 
Dulbecco`s Phosphate Buffered Saline (DPBS) and deionized water three times each. 
Upon washing, sponge was lyophilized. The cleavability of the sponge was confirmed 
by further incubation of the sponge in 10 mM tris(2-carboxyethyl) phosphine (TCEP) 
in cell culture medium adjusted to pH 7.4. 
 
5.2.5 Physiochemical characterization of HPCSS Gal macroporous sponges 
5.2.5.1 X-Ray photoelectron spectroscopy 
X-Ray photoelectron spectroscopy was used to qualitatively verify galactose 
ligand conjugation onto the HPCSS sponge.  Measurements were made on a VG 
ESCALAB Mk II spectrometer with a MgKa X-ray source (1253.6 eV photons) at a 
constant retard ratio of 40.  
5.2.5.2 Elastic modulus measurement 
The elastic modulus of the sponge was measured by atomic force microscopy 
(Bioscope Catalyst, Veeco Instruments, Santa Barbara, CA) in deionized water. A 
hybrid Atomic Force Microscopy (AFM) probe consisting of a silicon nitride 
cantilever and a silicon tip (ScanAsyst-Fluid, Veeco Probes, Camarillo, CA) was used. 
The deflection sensitivity was calibrated by ramping force-distance curves on a glass 
surface, and the spring constant was calibrated by the thermal noise method. After 
calibration, 128 x 128 force-distance curves were recorded over an area of 5 µm x 5 
µm by force volume. Each force-distance curve was analyzed by fitting to the Hertz 
model with conical tip geometry and Poisson ratio of 0.5. The obtained elastic moduli 
from each force-distance curve were mapped into a bitmap image with 128 x 128 
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pixels. The curve fitting and statistical analysis was implemented by a self-developed 
Fortran program.  The relationship between elastic modulus with the measured force 






= , where F is the measured force, E is Young’s 
elastic modulus, v is the Poisson ratio of the material under measurement (0.5 was 
used in the data processing), α is the half angle of the probe (22°) and δ is the sample 
deformation/ indentation..  
5.2.5.3 Scanning electron microscopy  
Top and cross section views of the sponge surface morphology and porosity 
were captured using SEM (JEOL JSM- 5600, Japan) at 10 kV. High magnification of 
SEM (15,000 folds) was performed to observe the sponge surface sub-micron features. 
Prior to imaging, the dried sponge was sputter coated with platinum for 90 seconds. 
Pore size distribution of the sponges was quantified with imageJ software (version 
1.43u) from collective SEM top view images of the sponges. 
5.2.5.4 Water uptake and sponge porosity measurements 
The lyophilized sponges were soaked in deionised water at room temperature 








= , where Wh is the hydrated weight and Wd is the 
dehydrated weight. The porosities of lyophilized HA Gal sponges were determined by 
solvent replacement. Samples were soaked in absolute ethanol for 24 hours and 
weighted after excess ethanol on the surface was blotted. It was noted that there were 
no significant changes in dimension before and after immersion in ethanol. The 





= , where M1 and M2 are the 
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weight of sponge before and after immersion in absolute ethanol, respectively; ρ is the 
density of absolute ethanol and V is the volume of sponge.  
5.2.5.5 Fourier transform infrared spectroscopy  
Infrared spectra were recorded on a Perkin Elmer Spectrum 100 FTIR (Fourier 
transform infrared) spectrometer. The disulfide to thiol exchange upon sponge 
cleavage was identified at wavenumber 2550 cm-1 [240]. 
5.2.5.6 Ellman’s thiol analysis 
Crosslinked HPCSS gel was completely cleaved with 25 mM DTT in DPBS at 
room temperature for 90 min and was further dialyzed using a Spectra/Pore 
membrane (molecular weight cutoff 12-14,000) for 3 days to remove DTT. The dried 
decomposed product was obtained by lyophilizing the solution for 3 days. The 
decomposed product (0.15 mM) was dissolved in 2.4 mL of 0.1 M Tris–HCl/0.01 M 
EDTA buffer (pH=8.0) and 100 µL of 0.01 M 5,5′-dithio-bis(2-nitrobenzoic acid) 
(DTNB) (Sigma, USA)/0.05 M DPBS (pH=7.0) was added to the solution. The 
absorbance of the solution at 412 nm was measured by Agilent 8453 UV Visible 
System and readings were compared with 0.05 mM TCEP (as positive control), 0.15 
mM cystamine (as negative control) and 0.15 mM uncleaved pre-crosslinked HPCSS 
polymer. 
5.2.5.7 Sponge cleavage condition optimization 
For easy visualization during cleavage, HPCSS Gal sponges were pre-soaked in 
0.25 mg/mL propidium iodide overnight (Molecular Probes, USA). The stained 
sponges were incubated with 3 mL of TCEP per sponge at various concentrations (25, 
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10, 5, 3 and 1 mM) in 37°C, 5% CO2 and 95 % incubator. The morphological changes 
of the sponge were monitored visually every 15 minutes.  
5.2.5.8 Dynamic visualization of sponge cleavage with time lapse imaging  
The propidium iodide-prestained HPCSS Gal sponges were incubated with 10 
mM TCEP and its macroporosity changes were monitored by Olympus fluoview 
FV1000 equipped with 37°C heated chamber with a 60x water lens for 30 minute 
with 2 minute time interval. Images were analysed using IMARIS and images 
assembled using Adobe illustrator CS3. 
 
5.2.6 Cell culture 
Hepatocytes were isolated from male Wistar rats weighing 250-300 g using the 
in situ collagenase perfusion method [182]. Animals were handled according to the 
IACUC protocols approved by the IACUC committee of National University of 
Singapore. Viability of hepatocytes was determined to be >90% by the Trypan Blue 
exclusion assay. Yields were approximately 108 cells/rat.  Freshly isolated rat 
hepatocytes were seeded onto the sponge by simply dropping the cell suspension on 
the sponge surface (0.5 x 106 cells per 55 µL cell suspension per 10 mm diameter 1 
mm thick sponge). The cell suspension was slowly absorbed into the sponge interior 
due to the inherent hydrophilicity of the sponges. Fresh cell medium was added 
slowly to the sponge edge after 45 minutes incubation (500 µL per sponge in 24-well 
plate). Hepatocytes seeded on a collagen monolayer platform (0.29 mg/mL collagen 
concentration) were used as control. Cells were maintained with Williams’ E medium 
supplemented with 10 mM NaHCO3, 1 mg/mL BSA, 10 ng/mL of EGF, 0.5 mg/mL 
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of insulin, 5 nM dexamethasone, 50 ng/mL linoleic acid, 100 units/mL penicillin, and 
100 mg/mL streptomycin and were incubated with 5% CO2 at 37°C and 95 % 
humidity. Medium was replenished every day.  
 
5.2.7 TCEP toxicity study in primary rat hepatocyte 
Primary rat hepatocyte was seeded on collagen coated well in 24-well plate 
format (0.3 x 106 cell per well). The culture was maintained for 3 days and the 
medium was replenished every day. On the 3rd day, the cells were incubated with 
TCEP solution in Williams’ E medium at pre-determined concentrations and time; 5 
mM for 1.5 hour, 10 and 25 mM for 1.5 hour each.  The duration of the incubation 
was chosen based on the ability of the associated TCEP concentrations to completely 
cleave HPCSS Gal sponge. Upon incubation, the morphology of the cells was 
monitored and followed with further incubation of 1 mg/mL (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution for 3 h.  The formed formazan 
product in each well was dissolved with 300 µL of 0.04 M HCl in isopropanol and its 
optical density was measured by TECAM Infinite M1000 microplate reader at 570 nm.  
Cell viability was determined by calculating the ratio of treated sample absorbance 







5.2.8 Hepatocyte spheroids characterization and functional assessment 
5.2.8.1 Spheroids size distribution 
Spheroid size distribution was quantified using imageJ software (version 1.43u)  
from collective phase contrast images of living hepatocyte spheroids cultured in the 
HPCSS Gal sponges on day 1, 3, 5 and 7. 
5.2.8.2 Hepatocyte spheroids retrieval by cleaving the HPCSS Gal sponge 
Rat hepatocyte spheroids were retrieved from the sponge by incubating cell 
seeded-cleavable sponge with 3 mL of 10 mM TCEP in respective cell culture 
mediums in each well of 12-well plate for 30 min at 37°C (incubator set up 5% CO2 
and 95 % humidity).  The cleaved sponge solution from each well was mixed 
thoroughly by 3 mL plastic dropper and then transferred into 15 mL falcon tube. This 
solution was further diluted with 3 mL pre-warmed DPBS and centrifuged at 100 x g 
for 10 minutes.  This washing step was repeated three times to remove TCEP solution 
completely. Eventually, the retrieved hepatocyte spheroids were resuspended in fresh 
mediums and replated on collagen coated dish or poly-L-lysine coated dish for further 
assays or spheroids manipulation. 
5.2.8.3 Live/dead staining 
Spheroids were co-stained with Cell Tracker Green (CTG, 20 µM) (Molecular 
Probes, USA) and propidium iodide (PI, 25 µg/mL) (Molecular Probes, USA) to 
determine live and dead cells, respectively. Cells were incubated for 30 min at 37°C 
and then fixed with 3.7 % paraformaldehyde for 10 min at room temperature. 
Fluorsave (Merck Chemicals) was applied to the stained spheroids to minimize photo-
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bleaching. Images were acquired by confocal laser scanning microscopy (Zeiss 
LSM510, Germany) at 488 and 543 nm excitation wavelengths.  
5.2.8.4 Reverse transcriptase polymerase chain reaction  
RNA was extracted from hepatocytes cultured as 3D spheroids in HPCSS Gal 
sponges by RLT lysis buffer (Qiagen, Singapore). Total RNA concentration was 
quantified by a Nanodrop (Thermoscientific) and 1 µg of RNA was converted to 
cDNA by High Capacity RNA-to-cDNA (Applied Biosystems). Primers were 
designed using Primer 3 and real-time PCR was performed by using SYBR green fast 
master mix on a ABI 7500 Fast Real-Time PCR system (Applied Biosystems). Gene 
expression was calculated using the ΔΔCT method normalized to β-actin. The primers 
used in experiment are shown below.  
Table 6. Primer sequences used in RT-PCR experiments 
CYPs 
























CYP: Cytochrome P450  




5.2.8.5 Immunofluorescence microscopy 
To stain F-actin, E-cadherin and MRP2, hepatocytes spheroids cultured for 72 
hours post-seeding in the sponges and retrieved from HPCSS Gal sponges were fixed 
in 3.7 % paraformaldehyde for 10 min. For staining F-actin, the cells were 
permeabilized for 5 min in 0.1 % Triton X-100 and incubated with 1 µg/mL TRITC-
phalloidin (Molecular Probes, USA) for 20 min.  For E-cadherin and MRP2 staining, 
following washing and blocking with 2% BSA/0.2% Triton-X 100 the spheroids were 
incubated overnight at 4°C with primary antibodies: anti-rat E-cadherin (BD, USA) 
and rabbit anti-rat MRP2 (Sigma Aldrich, Singapore), respectively. Secondary 
antibodies used were goat anti-mouse and goat anti-rabbit 488 and 555 (Molecular 
Probes, USA), respectively. Nuclei stain was captured using DAPI stain (Vecta Shield, 
UK). Images were captured using Olympus fluoview FV1000 with a 60x water lens. 
Images were analysed using IMARIS and assembled using Adobe illustrator CS3.  
5.2.8.6 Biliary excretion of fluorescein dye 
For monitoring hepatocyte repolarization, we visualized the excretion of 
fluorescein dye via bile canaliculi. Hepatocytes spheroids retrieved from the cleaved 
sponge were incubated with 15 µg/mL fluorescein diacetate (Molecular Probes, USA) 
in Williams’ E medium at 37 °C for 45 min. The cultures were then rinsed and viewed 
with a 63X water lens on a Zeiss Meta 510 confocal microscope.  
5.2.8.7 Scanning electron microscopy 
Hepatocyte spheroids retrieved from cleavable HPCSS Gal sponge and non 
cleavable HA Gal sponge control on day 3 were fixed with 3.7 % paraformaldehyde 
overnight and stained with 1% OsO4 for 1 hour. Samples were then dehydrated step-
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wise with ethanol (25 %, 50 %, 75 %, 90 % and 100 %) for 10 minutes each, dried in 
a vacuum oven and sputter coated with platinum for 90 seconds. The samples were 
viewed with a scanning electron microscope (JEOL JSM- 5600, Japan) at 10 kV. 
 
5.2.9 Statistical analysis 
Statistical comparisons were undertaken using paired two-tailed Student’s t tests. 
Results are expressed as mean ± standard deviation or standard error of the mean. 
Confidence interval to be significantly different is 95%.  
 
5.3 Results  
5.3.1 Versatility of hydroxypropyl cellulose chemistry facilitates conjugation of 
cleavable disulfide bonds 
The first step in the chemical synthesis of the cleavable cellulosic sponges 
(HPCSS sponge) involved the conjugation of dithiodipropionic acid onto 
hydroxypropyl groups of hydroxypropyl cellulose to provide carboxylic acid group (-
COOH) to further react with 2-amino ethyl methacrylate hydrochloride. This reaction 
was inspired by the Steglich esterification reaction with 4-dimethylaminopyridine 
(DMAP) as the catalyst to conjugate carboxylic group into alcohol group [245]. The 
second step in the synthesis was the conjugation of 2-amino ethyl methacrylate 
hydrochloride onto carboxylic acid group. Conjugated methacrylate group acted as 
crosslinking site during γ irradiation, similar function as the allyl group described 
previously [15]. The galactose conjugation onto the remaining available 
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hydroxypropyl groups was performed using 1,1’-carbonyldiamidazole in acetone. The 
sponge chemical synthesis and fabrication are depicted in detail in figure 32.  
 




Conjugated dithiodipropionic acid presence on the chemical backbone was 
verified by 1H NMR by identifying singlet peak at ~9.5 to 10 ppm (Step 1, figure 33).  
In estimation, there was at least 1 conjugated dithiodipropionic acid group in every 6 
subunits of HPC. Upon further conjugation of 2-amino ethyl methacrylate 
hydrochloride in the step 2, this singlet peak disappeared. Based on calculation, the 
conjugated methacrylate group appeared in every 16 subunits of HPC. Multiplet peaks 
appeared at ~5 to 5.5 ppm indicated successful conjugation of methacrylate group 




Figure 33. Cleavable sponge chemical structure validation by 1H NMR  
Galactose presence on the chemical backbone was quantified by N1s scan XPS. 
An XPS spectrum showed increased nitrogen atomic counts after conjugation (~0.6 % 




Figure 34. N1s XPS analysis of conjugated galactose indicates the net increase of 
N1s counts after conjugation 
 
Surface morphology and porosity of the sponges were characterized using SEM 
images. Image analysis of the sponge porosity revealed the majority of pore size to be 
between 71 to 90 µm; ~22% and ~28% of pores were 71-80 µm and 81-90 µm, 
respectively (figure 35D). These pores were then within diffusible dimension (< 200 
µm). The sponge also had considerably high water uptake (96.8 ± 0.14%) with 
porosity 88.69 ± 5.92%. Measurement of the elastic modulus of the sponges using 
atomic force microscopy revealed an average modulus of 30 kPa. This modulus was 
found to be slightly higher compared to the previous non-cleavable sponge but still 
considered to be as soft matrix. High magnification images of the sponge surface 
revealed surface sub-micron features in the range of 0.5 µm scale which was proven 
previously to help tethering the hepatocyte spheroids to the sponge (figure 35B insert) 
[80]. The dry sponge was soaked in 0.25 mg/mL propidium iodide solution to stain 
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the sponge’s macroporous structure. By laser confocal microscopy, we observed that 
the macroporosity was maintained as a hydrated macroporous network structure in an 
aqueous environment (figure 35C) in contrast to typical hydrogels that lose their 
porosity in an aqueous environment.  
 
Figure 35. Sponge physical characteristics: a) Sponge top view (scale bar in cm), b) 
SEM images of the sponge surface porosity (insert image is the surface sub-micron 
features view), c) Sponge aqueous macroporosity (scale bar 50 µm) and d) Sponge 
pore size distribution (Data are average ± standard deviation, n=50) 
5.3.2 Conjugated disulfide bonds on the side chain of hydroxypropyl cellulose 
induces cleavability of macroporous cellulosic sponge rapidly at physiological 
condition 
Upon successfully inserting disulfide bond onto hydroxypropyl cellulose side 
chain, the cleavability of the sponge in reductants was tested. Sponge samples before 
and after cleavage were compared and analyzed by FTIR. FTIR spectra showed the 
valley-like peak appearance at 2550 cm-1, similarly as it was reported previously in 
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another disulfide-containing hydrogel (figure 36A) [240]. This peak corresponded to 
thiol group (-SH) formation from disulfide group (-S-S-) upon cleavage. The thiol 
group formed was further confirmed by Ellman’s thiol analysis in terms of its ability 
to further cleave a known disulfide-containing dye 5,5'-dithiobis-(2-nitrobenzoic acid) 
(DTNB) to be UV-detectable compound. The cleaved sponge sample was found to be 
able to cleave DTNB at 1/3rd strength of the positive control, TCEP (figure 36B).  
 
 
Figure 36. Sponge cleavage characterizations: a) FTIR analysis indicates the presence 
of valley at 2550 cm-1, b) Ellman’s thiol analysis shows the ability of thiol groups of 
the cleaved HPCSS sponge to further cleave 5,5'-dithiobis-(2-nitrobenzoic acid) 
indicated by UV absorbance at 412 nm and c) Physical morphology changes of 
HPCSS Gal sponge upon addition of tris(2-carboxyethyl) phosphine (TCEP) at 





After confirming the formation of thiol groups from disulfide groups upon 
cleavage, the optimum cleavage condition was determined by incubating the sponge 
with serial concentrations of TCEP. Physical morphology changes of the sponge were 
monitored visually (figure 36C). To ease the monitoring process, the sponges were 
pre-soaked overnight with 0.25 mg/mL propidium iodide. TCEP could cleave the 
sponge as fast as 30 min (table 7). The optimum cleavage condition was determined 
by the time taken for cleavage as well as reductant concentration used.  TCEP, a 
reductant without thiol group, had been favoured over thiol-based reductants due to its 
less cytotoxicity and less ability to penetrate cell membrane [246, 247]. Therefore, 10 
mM TCEP was chosen as optimum condition for further sponge cleavage (~30 min 
cleavage).  
Table 7. Optimization of cellulosic sponge cleavage using different concentrations of 
reductant 
TCEP concentrations in 
William’s E medium 
Remarks 
25 mM Sponge is cleaved within 30 minute 
10 mM Sponge is cleaved within 30 minute 
5 mM Sponge is cleaved within 1.5 hour 
3 mM Sponge is cleaved within 2 hours 
1 mM Sponge not cleaved 
 
Sponge aqueous macroporous network disappearance was monitored 
dynamically by time lapse imaging in confocal microscopy. This salient feature of the 
cellulosic sponge was monitored within 30 minutes duration with image taken every 2 
minute time interval. As it is shown in figure 37, 6 minutes after adding 10 mM 
TCEP, the sponge macroporous networks had shrunken significantly. At 20 minutes, 
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macroporosity had completely vanished with significant drop in the total signal 
intensity. This decrease corresponded to sponge thinning and dissolution during 
cleavage.  
 
Figure 37.  Dynamic observation of sponge cleavage with 10 mM TCEP. Aqueous 
macroporosity disappears after 30 minute incubation with 10 mM TCEP (scale bar 
200 µm) 
 
The intended applications of this cleavable cellulosic sponge were for 3D 
spheroids culture as well as its cleavability to retrieve the spheroids for further 
manipulations. This proposed mechanism is show in figure 38. During cleavage, 
disulfide bonds exchanged into thiol bonds, loosen up the crosslinked bond and made 
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the sponge soluble. The cleavage should only occur on-demand upon adding the 
disulfide bond reductant.  
 
Figure 38. Schematic drawing of cleavable cellulosic sponge cleavage mechanism 
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5.3.3 Reductant used to cleave the sponge is relatively non-cytotoxic even into 
sensitive cell type (primary hepatocytes) 
The cytotoxicity of TCEP was investigated by incubating TCEP with the 
associated time needed to completely cleave the sponge; 10 mM in 30 min. Since the 
application for this cleavable sponge was mainly for primary cell culture, primary rat 
hepatocyte cultured in collagen monolayer was used in the cytotoxicity study. 
 
Figure 39. TCEP toxicity in rat hepatocyte indicates good maintenance of cell 
viability ( > 80%) (scale bar 100 µm). Incubation time was determined by the 
associated time needed to completely cleave the sponge. Data are average ± standard 
deviation of 3 independent experiments. 
 
As it is shown in figure 39 left panel, primary rat hepatocyte viability upon 30 
minutes incubation of 10 mM TCEP is 87.42 ± 8.03 %. Phase contrast images of 
hepatocytes with and without TCEP incubation at the right panel clearly show the 
maintenance of cuboidal cell shape and bile canaliculi-like structure at cell-cell 
contact. No significant cell damage was observed. 
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5.3.4 Characterization of the hepatocyte spheroids cultured in cellulosic sponges  
5.3.4.1 Primary rat hepatocytes form compact hepatocyte spheroids in the 
cleavable cellulosic sponge within 24 hours post-seeding 
Similarly as it was shown previously in non-cleavable sponge (HA Gal sponge), 
in cleavable HPCSS Gal sponge, primary rat hepatocytes also immediately 
reorganized into 3D spheroids within 1 day of culture and remained stable in this 
configuration until at least day 7 (figure 40). Hepatocyte spheroids formed in the 
HPCSS Gal sponges were 88.77 µm in average diameter. The spheroids formed in 
HPCSS Gal sponges were constrained in the sponge macropores and thus did not 




Figure 40. Rat hepatocytes cultured in cleavable HPCSS Gal sponge. Compact 
spheroids are formed within one day post-seeding (scale bar 100 µm). Average 
spheroids size on day 1: 75.58 ± 16.61 µm, day 3: 84.68 ±17.64 µm, day 5: 96.95 ± 
13.52 µm and day 7: 97.88 ± 11.84 µm (Data are average ± standard deviation of 20 
spheroids) 
 
Hepatocyte spheroids viability, which was assessed by co-staining the cells with 
Cell-Tracker Green (CTG) and Propidium Iodide (PI), showed majority of green 
signals which revealed good viability maintenance at least 7 days in culture (figure 
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41). The CTG signals illustrated indistinguishable borders between single cells in the 
spheroids, which reflected the tightness of the cell-cell contacts.  
 
Figure 41. Live/dead staining of rat hepatocyte spheroids in the cleavable sponge 
(projected spheroid images, scale bar 20 µm) 
 
5.3.4.2 Retrieved hepatocyte spheroids from cleavable cellulosic sponges could be 
retrieved by cleaving the sponge without imposing cytotoxicity 
The effect of sponge cleavage to the characteristics of retrieved spheroid was 
investigated towards the downstream effects e.g. maintenance of cytochrome P450 
genes, polarity marker, tight cell junction, spheroids compactness and bile excretory 
function. The maintenance of important rat cytochrome P450 genes (CYP1A2, 
CYP2B2 and CYP3A2) was analyzed based on the effect of TCEP incubation into 
short term and long term culture/post-replating. Hepatocyte spheroids cultured in non-




Figure 42. Gene expressions analysis of rat hepatocyte cultured in cleavable HPCSS 
Gal sponge indicates no significant effect of the incubation of 10 mM TCEP towards 
CYP450 enzymes.	  Data are average ± standard error of the mean from 3 independent 
experiments (N.S.: not significantly different) 
 
Rat hepatocyte spheroids incubation with 10 mM TCEP for 30 minute did not 
show any significant detrimental effect to the 3 CYP genes (figure 42). There was 
slight drop in the fold expression changes of CYP genes upon cleaving the HPCSS 
Gal sponge to retrieve the spheroids (~2 fold decrease). However, upon overnight 
replating these retrieved spheroids on poly-L-lysine coated dish, the spheroids 
rejuvenated the gene expressions comparable to the spheroids cultured in non-
cleavable sponge.  
Immunofluorescence staining of F-actin, E-cadherin and MRP2 in the 
hepatocyte spheroids 72 hours post seeding retrieved from cleavable (HPCSS Gal) 
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sponges and in non-cleavable (HA Gal) sponge and showed comparable localization 
of these markers (figure 43). As would be expected in non-spreading cells, F-actin 
staining revealed that the actin cytoskeleton had a predominant cortical localization in 
the spheroids and an absence of stress fibers. E-cadherin staining, a marker of cell-cell 
adhesions demonstrated that cells in the hepatocyte spheroids have tight associations 
between neighbouring cells. MRP2 staining marked the apical domains of the 
polarized hepatocytes. In MRP2 staining image (figure 43 rightmost panel), the 
signals showed a comparable signal as observed in the intact hepatocyte spheroids in 
the non-cleavable sponge and retrieved spheroids from cleavable sponge.  
Figure 43. Immunofluorescence staining of polarity markers and cell-cell adhesions 
of hepatocyte spheroids retrieved from cleavable HPCSS Gal sponge and cultured in 
non-cleavable HA Gal sponge. The incubation of 10 mM TCEP to cleave the sponge 
does not show harmful effect to these markers (projected spheroid images, scale bar 
20 µm) 
 
Upon confirming the maintenance expression of MRP2 (apical domain marker 
as well as hepatocyte efflux transporter) in the retrieved spheroids, the excretory 
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function of these spheroids was studied by incubating the spheroids with fluorescein 
diacetate (FDA). Viable cells in the spheroids will cleave FDA into fluorosecein dye 
by intracellular esterases which then be excreted by MRP2 into the bile canaliculi. 
FDA staining of the retrieved hepatocyte spheroids showed dye accumulation in the 
bile canaliculi region between the two cells (figure 44). This excretion exhibited 
similarity to what had been observed in the intact hepatocyte spheroids in non-
cleavable sponge [80].  
 
Figure 44. FDA staining of the retrieved rat hepatocyte spheroids from cleavable 
HPCSS Gal sponge indicates putative accumulation of dye at the bile canaliculi 
region (projected spheroid images, scale bar 20 µm) 
 
The maintenance of spheroids compact morphology upon retrieving was again 
confirmed by SEM. The retrieved hepatocyte spheroids still showed surface 
smoothness and disappearance of the cell-cell boundaries, compared to the spheroids 
cultured in non cleavable sponge (figure 45).  
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Figure 45. Comparison of rat hepatocyte spheroids SEM images obtained from both 
cleavable HPCSS Gal sponge and non-cleavable HA Gal sponge indicates no surface 
morphology difference 
 
5.3.4.3 Retrieved hepatocyte spheroids show replatability and easy manipulation  
The applicability of the retrieved spheroids obtained by cleaving the sponge was 
demonstrated by replating the spheroids on two different kinds of coated dishes; 
collagen and poly-L-lysine-coated dishes. These two kinds of coated dishes 
theoretically will either induce spheroids spreading or prevent spheroids spreading, 
respectively.  
Upon spheroids replating on collagen coated dish, the spheroids settled on the 
bottom of the dish within 1 hour. 4 hours post-replating, the spreading pattern of the 
spheroids was clearly observed at the spheroids periphery (figure 46). And 16 hours 
later, the spheroids had exhibited an almost complete spreading. Some cells in the 
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spheroids core did not manage to spread on the collagen gel possibly due to hindrance 
imposed by cells beneath them. Cells which were spreading out of the spheroids 
showed the clear bile canaliculi-like structure at the cell-cell boundary, which was 
normally seen on hepatocyte collagen monolayer culture. 
 
 Figure 46. Retrieved rat hepatocyte spheroids replated on collagen dish show 
the ability to spread (insert image is the zoomed in view of the spheroid) 
 
Instead of allowing the spheroids to spread, the spheroids compact morphology 
could be maintained for extended period by replating them on poly-L-lysine coated 
dish. Positively charged polymer such as poly-L-lysine has been known to anchor 
hepatocyte spheroids but prevent spheroid spreading [248]. When the hepatocyte 
spheroids were retrieved and replated on poly-L-lysine coated dish, the spheroids 
settled at the bottom of the dish and remained as intact round spheroids (figure 47 
upper panel). The spheroids also showed good cell viability upon replating (projected 





Figure 47. Retrieved hepatocyte spheroids can also be replated on poly-L-lysine dish 
to prevent spheroids from spreading (lower panel is the projected spheroid images) 
 
5.4 Discussion 
We have conjugated disulfide bonds onto side chain group of hydroxypropyl 
cellulose to create cleavable hydrogel-based sponge. This strategy has shown 
successful rapid and easy cleavage of cellulosic sponge without hindering the ability 
of hydroxypropyl cellulose to be crosslinked by γ irradiation and formed macroporous 
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sponge.  The sponge is fabricated without chemical cross-linkers, yet cross-linked 
through stable chemical bonds [15]. Made of a water soluble precursor, our cleavable 
cellulosic hydrogel sponges are very hydrophilic thus acting as a non-adhesive matrix 
and preventing cell spreading, which is important for maintenance of the mature 
hepatocyte phenotype [181].   
The sponge was also easy to be galactosylated for specific hepatocyte culture 
application. Unlike other hydrogels, the macroporous networks in our cellulosic 
sponge support the in situ formation and maintenance of polarized hepatocyte 
spheroids [33, 199, 200]. The cellulosic sponge, which acts as a hepatocyte 
substratum anchor, did not prevent cell aggregation, as would normally happen in cell 
culture hydrogel with excessive extracellular matrix presentation [201]. The galactose 
presented chemical cues to the hepatocytes to reorganize into 3D spheroids within 1 
day post-seeding, while the macroporous structure constrained them physically.  Since 
the galactose ligand only interacts weakly with ASGPR receptors in the hepatocyte 
cell membrane [175], it is the combination of the physical and chemical cues in the 
sponge which is important in establishing stable constrained hepatocyte spheroids.   
The cleavable sponge still exhibited soft hydrogel mechanical stiffness 
characteristic (E ≈ 30 kPa) with excellent water uptake (> 95%) despite the alteration 
of side chain chemistry with disulfide bond. Excellent sponge water uptake combined 
with sponge durable macroporosity had helped in rapid solution exchange when the 
sponge was incubated with reductant solution, thus induced rapid sponge cleavage. 
Unlike other disulfide-containing hydrogels which need longer reductant incubation, 
our cleavable cellulosic sponge showed complete cleavage within 30 minute with 
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comparable reductant concentration used [240].  We thus ensured short exposure of 
the cells to reductant solution.  
Hepatocytes cultured as 3D spheroids in the cleavable cellulosic sponge were 
constrained within sponge macroporosity. They exhibited maintenance of cell 
viability for at least 7 days in culture. When these spheroids were retrieved from the 
sponge through cleavage, important drug metabolizing enzymes, CYP1A2, CYP2B2 
and CYP3A2, were not affected by TCEP used for cleaving the sponge and the 
enzymes expressed were comparable to the hepatocyte spheroids cultured in the non-
cleavable comparator sponge. In addition, polarity marker (cortical F-actin), tight cell-
cell adhesions, apical hepatocyte marker (MRP2), biliary excretory function and 
spheroid compact morphology were not affected by the cleavage process.  
Upon retrieval, hepatocyte spheroids showed facile manipulations towards 
replatable living spheroids either on collagen coated or poly-L-lysine coated dishes.  
On collagen dish, the spheroids started to settle and spread within 20 hours post-
replating, with clear bile canaliculi-like appearance at the cell-cell boundary. While 
on positively charge surface, poly-L-lysine dish, the spheroids maintained as compact 
spheroids without visible spheroids spreading. The cell viability was well maintained 
after overnight replating. Overall, our cleavable cellulosic sponge provided the facile 
hydrogel-based sponge platform to culture primary rat hepatocytes as 3D spheroids 







We have synthesized and fabricated a cleavable macroporous cellulosic 
hydrogel sponge conjugated with galactose as a platform to culture primary rat 
hepatocytes as 3D spheroids with the ability to retrieve the spheroids at physiological 
condition. Hepatocyte spheroids retrieval is performed through rapid non-cytotoxic 
sponge cleavage. The soft macroporous structure of cleavable cellulosic sponge 
conjugated with galactose facilitates the formation of hepatocyte spheroids by 
presenting both the mechanical cues (via matrix rigidity) and chemical cues for the 
hepatocytes to reorganise into 3D spheroids within 24 hours post-seeding. The 
constrained hepatocyte spheroids maintain cell viability for at least a week of culture. 
Upon spheroids retrieval through sponge cleavage, polarized hepatocyte phenotypes 
are well maintained; drug metabolizing enzymes (CYP1A2, CYP2B2 and CYP3A2), 
polarity marker (cortical F-actin), tight cell-cell adhesions, apical hepatocyte domain 
marker (MRP2), biliary excretory function, spheroid compact morphology and cell 
viability. The living retrieved spheroids are replatable on both collagen coated and 
poly-L-lysine coated dishes for further use. As many of tissue engineering-related 
researches require temporary synthetic scaffold matrix such as stem cell 
differentiation and in vitro organoid and thick tissue culture, this technology offers 
useful platform to culture cells as 3D spheroid construct with easy, rapid and 







CONCLUSION AND DIRECTION FOR FUTURE INVESTIGATIONS 
 
6.1 Conclusion 
This thesis has covered the development progress of the macroporous cellulosic 
sponge made of cellulose derivative, hydroxypropyl cellulose, as novel multi-well 
format 3D hepatocyte culture platform and its applications in drug safety testing and 
HCV entry study. The last part of this development covers the latest generation of the 
cellulosic sponge towards cleavable sponge as 3D hepatocyte culture platform with 
spheroids retrieval capability.  
Primary rat hepatocyte reorganized into compact spheroids within 7 hours post-
seeding in the galactosylated cellulosic sponge and exhibited excretory function 
within 16 hours. The spheroids were constrained in the sponge macroporosity over 
extended culture. These constrained hepatocyte spheroids maintain cell viability, cell 
polarity markers, and 3D cell morphology. These correlated with enhanced 
hepatocyte-specific functions and expression of drug metabolic enzymes and drug 
transporters. Hepatocyte spheroids grown in the sponge also show inducibility of 
various drug metabolizing enzymes including CYP1A2, CYP2B2 and CYP3A1. The 
sponge has comparable or lower drug absorbency compared to other cell culture 
platforms. Importantly, sponge fabrication is amenable for large-scale production and 
high-throughput screening. Cell seeding into the sponge involves simple steps similar 
to high-throughput 2D cell cultures. 
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Similarly, primary human hepatocyte and Huh 7.5 spheroids were formed in the 
sponge within 24 hours post-seeding and constrained in the sponge macroporosity for 
prolonged culture. The size of the spheroids was maintained within mass transfer 
barrier-free range. Spheroids viability was well maintained up to 5 and 2 weeks for 
human hepatocyte and Huh 7.5, respectively. The compact spheroids morphology was 
observed at least up to 2 weeks of culture. Compact spheroids morphology correlated 
well with gene expression showing minimal dedifferentiation of human hepatocyte 
spheroids and upregulation of mature hepatocyte genes in Huh 7.5 spheroids. Both 
types of spheroids expressed liver polarity markers and HCV entry markers. When 
these spheroids were inoculated with HCVpp, an available in vitro model to study 
HCV entry, ~80% of the spheroids were infected with HCVpp distributed throughout 
whole spheroids region. These spheroids had also shown the ability to be infected at 
prolonged culture indicating the maintenance of HCV entry markers. By co-
incubating both types of spheroids with HCVpp and CD81 antibody, HCVpp entry 
was inhibited at dose-dependent manner. Together, this spheroids model provides a 
useful platform to study HCV entry and inhibition in vitro and to screen HCV 
antiviral candidates.  
Lastly, we have demonstrated the usefulness of hydroxypropyl cellulose 
chemical versatility towards functionalization with reducible disulfide bond to design 
a cleavable cellulosic sponge. We have synthesized and fabricated a cleavable 
macroporous cellulosic hydrogel sponge conjugated with galactose as a platform to 
culture primary rat hepatocytes as 3D spheroids with the ability to retrieve the 
spheroids at physiological condition. Hepatocyte spheroids retrieval was performed 
through rapid non-cytotoxic sponge cleavage. The soft macroporous structure of 
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cleavable cellulosic sponge conjugated with galactose facilitated the formation of 
hepatocyte spheroids by presenting both the mechanical cues (via matrix rigidity) and 
chemical cues for the hepatocytes to reorganise into 3D spheroids within 24 hours 
post-seeding. The constrained hepatocyte spheroids maintained cell viability for at 
least a week of culture. Upon spheroids retrieval through sponge cleavage, polarized 
hepatocyte phenotypes were well maintained; drug metabolizing enzymes (CYP1A2, 
CYP2B2 and CYP3A2), polarity marker (cortical F-actin), tight cell-cell adhesions, 
apical hepatocyte domain marker (MRP2), biliary excretory function, spheroid 
compact morphology and cell viability. The living retrieved spheroids were replatable 
on both collagen coated and poly-L-lysine coated dishes for further use.  As many of 
tissue engineering-related researches require temporary synthetic scaffold matrix such 
as stem cell differentiation and in vitro organoid and thick tissue culture, this 
technology offers useful platform to culture cells as 3D spheroid construct with easy, 
rapid and physiological removal of bulk synthetic sponge. 
Altogether, we have generated a novel class of hydrogel-based macroporous 
sponge for 3D hepatocyte-based applications in specific and for other soft tissue 
cultures in general. This sponge provides a relatively easy-to-synthesize, economic 
and amenable platform to be fabricated in large scale. Cell seeding is rather easy with 
possible manipulation towards robotic liquid handler-assisted seeding. 
 
6.2 Direction for future investigations 
Future directions for further investigations utilizing this sponge as 3D cell 
culture model will be firstly to further improve the sponge design and cell seeding 
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technique. The solution to improve current cell loading upon seeding needs to be 
thought.  A possible way is to create leak-proof sponge by coating additional gel on 
the outer surface of the sponge. A thorough investigation on the effect of sponge 
thickness to the penetration depth of the seeded cells will be useful, since the current 
sponge design thickness was not varied. And cell seeding using robotic liquid 
handler-seeding also can improve the cell seeding variation into large number of 
sponges for vast multi-well assays and less time consuming experiments. 
Secondly for drug safety testing usage of this sponge, since the hepatocyte 
spheroids could be cultured for prolonged period, it will be interesting to use this 
model as a chronic liver injury model which is normally challenged by the 
conventional 2D hepatocyte culture.  
Thirdly for HCV infection study, thorough investigation on HCV replication in 
primary human hepatocyte and Huh 7.5 spheroids in the prolonged culture is 
necessary. Since these spheroids are able to maintain the differentiated phenotypes for 
extended period, it will be interesting to observe if HCV could propagate and infect 
persistently in the spheroids. The persistence HCV infection becomes critical to study 
HCV transmission from infected cell to naïve cell. This study is currently being 
performed at Roche Nutley. 
Fourthly, the cell source issue also needs to be investigated. The cells used in 
this thesis were mainly primary cells; however it has been discussed in chapter 2 that 
primary cells face many limitation and scarceness. Experiments using readily 
available and commercial cells such as stem cells-derived hepatocytes will be exciting 
to get more reproducible data. 
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And lastly the cleavable sponge utility could still bring further extensive 
investigation towards several other researches such as a) in vivo culture of cell-seeded 
cleavable sponge. Since this sponge is cleavable by reductants, it will be interesting to 
observe how sponge cleavage occurs in the body naturally (body contains some 
amounts of natural reductants), b) 3D culture of cancer cells with the retrieval of 
tumor spheroids as engineered tumor model to study cancer metastasis in vitro or in 
vivo and c) sponge mechanical stiffness tunability by its cleavage is useful to study 
mechanical stiffness influences towards stem cell differentiation lineage. Sponge 
mechanical stiffness can be simply varied by cleaving the sponge at various degree of 
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created by the Order Confirmation and these terms and conditions or any rights granted hereunder, subject to the 
following exception. The exception: in cases where a person is specifically engaged by a second person to provide 
reproductions of Works to (and/or to obtain licenses on behalf of) the second person and EITHER (i) the first person 
expressly notifies the second person of its obligation not to redistribute or otherwise use the material without 
authorization, OR (ii) the second person is identified in the Order Confirmation as the publisher of the material to include 
the Work licensed under this service, then the license may be transferred to the second person and both the first person 
and the second person shall be jointly deemed to be the "User" under the Order Confirmation and these terms and 
conditions for that transaction. An organizational User and its principals, employees, agents and affiliates are jointly and 
severally liable for the performance of all payments and other obligations hereunder.
11.2: Amendment or Waiver, Objection to Contrary Terms. No amendment or waiver of any terms is binding unless set 
forth in a writing other than a standard User or CCC form and signed by the parties. The Rightsholder and CCC hereby 
object to any terms contained in any writing prepared by the User or its principals, employees, agents or affiliates and 
purporting to govern or otherwise relate to the licensing transaction described in the Order Confirmation, which terms are 
in any way inconsistent with any terms set forth in the Order Confirmation and/or in these terms and conditions or CCC's 
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thereof shall result in immediate termination of such license without further notice. Invoices are due and payable upon 
receipt. Any unauthorized (but licensable) use of a Work that is terminated immediately upon notice thereof may be 
liquidated by payment of the Rightsholder's ordinary license price therefore; any unauthorized (and unlicensable) use that 
is not terminated immediately for any reason (including, for example, because materials containing the Work cannot 
reasonably be recalled) will be subject to all remedies available at law or in equity, but in no event to a payment of less 
than three times the Rightsholder's ordinary license price for the most closely analogous licensable use plus Rightsholder's 
and/or CCC's costs and expenses incurred in collecting such payment.
11.4: Governing Law and Jurisdiction. The licensing transaction described in the Order Confirmation document shall be 
governed by and construed under the law of the State of New York, USA, without regard to the principles thereof of 
conflicts of law. Any case, controversy, suit, action, or proceeding arising out of, in connection with, or related to such 
licensing transaction shall be brought, at CCC's sole discretion, in any federal or state court located in the County of New 
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If you have any comments or questions about this pay-per-use service or Copyright Clearance Center, please contact us at 
978-750-8400 or send an e-mail to info@copyright.com.
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Permission type: Republish or display content  




1. The publisher for this  copyrighted material is Elsevier. By  clicking "accept"; in connection with completing this 
licensing  transaction, you agree that the following terms and conditions apply to this  transaction (along with the Billing 
and Payment terms and conditions  established by Copyright Clearance Center, Inc. ("CCC"), at the time  that you opened 




2. Elsevier hereby grants you  permission to reproduce the aforementioned material subject to the terms and  conditions 
indicated. 
 
3. Acknowledgement:  If any part of the material to be used (for example, figures) has appeared in  our publication with 
credit or acknowledgement to another source, permission  must also be sought from that source. If  such permission is 
not obtained then that material may not be included in your  publication/copies. Suitable acknowledgement to the source 
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must be made, either  as a footnote or in a reference list at the end of your publication, as  follows: "Reprinted  from 
Publication title, Vol /edition number, Author(s), Title of article /  title of chapter, Pages No., Copyright (Year), with 
permission from Elsevier  [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit -  "Reprinted from 
The Lancet, Vol. number, Author(s), Title of article, Pages  No., Copyright (Year), with permission from Elsevier.” 
 
4. Reproduction  of this material is confined to the purpose and/or media for which permission  is hereby given. 
 
5. Altering/Modifying  Material: Not Permitted. However figures and illustrations may be  altered/adapted minimally to 
serve your work. Any other abbreviations,  additions, deletions and/or any other alterations shall be made only with prior  
written authorization of Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com)  
 
6. If the permission fee for  the requested use of our material is waived in this instance, please be advised  that your 
future requests for Elsevier materials may attract a fee. 
 
7. Reservation of Rights:  Publisher reserves all rights not specifically granted in the combination of  (i) the license details 
provided by you and accepted in the course of this  licensing transaction, (ii) these terms and conditions and (iii) CCC's 
Billing  and Payment terms and conditions. 
 
8. License Contingent Upon  Payment: While you may exercise the rights licensed immediately upon issuance  of the 
license at the end of the licensing process for the transaction,  provided that you have disclosed complete and accurate 
details of your proposed  use, no license is finally effective unless and until full payment is received  from you (either by 
publisher or by CCC) as provided in CCC's Billing and  Payment terms and conditions. If full  payment is not received on a 
timely basis, then any license preliminarily  granted shall be deemed automatically revoked and shall be void as if never  
granted. Further, in the event that you  breach any of these terms and conditions or any of CCC's Billing and Payment  
terms and conditions, the license is automatically revoked and shall be void as  if never granted. Use of materials as  
described in a revoked license, as well as any use of the materials beyond the  scope of an unrevoked license, may 
constitute copyright infringement and  publisher reserves the right to take any and all action to protect its  copyright in 
the materials. 
 
9. Warranties: Publisher makes  no representations or warranties with respect to the licensed material. 
 
10. Indemnity: You hereby indemnify and agree to hold  harmless publisher and CCC, and their respective officers, 
directors, employees  and agents, from and against any and all claims arising out of your use of the  licensed material 
other than as specifically authorized pursuant to this license. 
 
11. No Transfer of License:  This license is personal to you and may not be sublicensed, assigned, or  transferred by you 
to any other person without publisher's written permission. 
 
12. No Amendment Except in Writing: This license may  not be amended except in a writing signed by both parties (or, in 
the case of  publisher, by CCC on publisher's behalf). 
 
13. Objection to Contrary Terms: Publisher hereby  objects to any terms contained in any purchase order, 
acknowledgment, check  endorsement or other writing prepared by you, which terms are inconsistent with  these terms 
and conditions or CCC's Billing and Payment terms and  conditions. These terms and conditions,  together with CCC's 
Billing and Payment terms and conditions (which are  incorporated herein), comprise the entire agreement between you 
and publisher  (and CCC) concerning this licensing transaction. In the event of any conflict between your  obligations 
established by these terms and conditions and those established by  CCC's Billing and Payment terms and conditions, 
these terms and conditions  shall control. 
 
14. Revocation: Elsevier or Copyright Clearance   Center may deny the  permissions described in this License at their sole 
discretion, for any reason  or no reason, with a full refund payable to you. Notice of such denial  will be made using the 
contact information provided by you. Failure to  receive such notice will not alter or invalidate the denial. In no event  will 
Elsevier or Copyright Clearance Center  be responsible or liable for any costs, expenses or damage incurred by you as a  
result of a denial of your permission request, other than a refund of the  amount(s) paid by you to Elsevier and/or 




The following terms and  conditions apply only to specific license types: 
 
15. Translation: This permission is granted for non-exclusive world English rights only unless your  license was granted for 
translation rights. If you licensed translation rights  you may only translate this content into the languages you 
requested. A  professional translator must perform all translations and reproduce the content  word for word preserving 
the integrity of the article. If this license is to  re-use 1 or 2 figures then permission is granted for non-exclusive world 
rights  in all languages. 
 
16. Website: The  following terms and conditions apply to electronic reserve and author websites: 
    Electronic reserve: If licensed material is to be posted to  website, the web site is to be password-protected and made 
available only to  bona fide students registered on a relevant course if: 
  This license was made in connection with a course, 
  This permission is granted for 1 year only. You may obtain a  license for future website posting,  
  All content posted to the web site must maintain the copyright  information line on the bottom of each image,  
  A hyper-text must  be included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at http://www.elsevier.com, and 
  Central Storage: This  license does not include permission for a scanned version of the material to be  stored in a central 
repository such as that provided by Heron/XanEdu.  
 
17. Author website for journals with the following additional clauses:  
All content posted to the web site must maintain the copyright information line on the bottom of each image, and the 
permission granted is limited to the personal version of your paper.  You are not allowed to download and post the 
published electronic version of your article (whether PDF or HTML, proof or final version), nor may you scan the printed 
edition to create an electronic version. A hyper-text must be included to the Homepage of the journal from which you are 
licensing at http://www.sciencedirect.com/science/journal/xxxxx . As part of our normal production process, you will 
receive an e-mail notice when your article appears on Elsevier’s online service ScienceDirect (www.sciencedirect.com).   
That e-mail will include the article’s Digital Object Identifier (DOI).  This number provides the electronic link to the 
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published article and should be included in the posting of your personal version.  We ask that you wait until you receive 
this e-mail and have the DOI to do any posting.  
  Central Storage:  This license does not include permission for a scanned version of the material  to be stored in a central 
repository such as that provided by Heron/XanEdu. 
 
18. Author website for books with the following additional clauses:  
  Authors are  permitted to place a brief summary of their work online only. 
  A hyper-text must  be included to the Elsevier homepage at http://www.elsevier.com . All content posted to the web site 
must maintain the copyright information line on the bottom of each image. You are not allowed to download and post the  
published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. 
  Central Storage:  This license does not include permission for a scanned version of the material to be stored in a central 
repository such as that provided by Heron/XanEdu. 
 
19. Website (regular and for author): A hyper-text must be included to  the Homepage of the journal from which you are 
licensing at http://www.sciencedirect.com/science/journal/xxxxx. or for books to the  Elsevier homepage at 
http://www.elsevier.com 
 
20. Thesis/Dissertation: If your license  is for use in a thesis/dissertation your thesis may be submitted to your  institution 
in either print or electronic form. Should your thesis be published  commercially, please reapply for permission. These 
requirements include  permission for the Library and Archives of Canada to supply single copies, on  demand, of the 
complete thesis and include permission for UMI to supply single  copies, on demand, of the complete thesis. Should your 
thesis be published  commercially, please reapply for permission.  
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Terms and Conditions for Permission Categories: "Deliver via ILL or Document Delivery" and "Photocopy for 
General Business or Academic Use" 
1. Scope of Authorization.
You may reproduce chapters and articles from the publications included in CCC's pay-per-use service by reporting those 
copies and paying the rightsholders' fees through CCC. Reproduction by photocopy machine is covered by this pay-per-use 
system of authorizations, as is the facsimile transmission of copies ("faxing", "telecopying" or equivalent technology).
2. Limitations on Use.
Authorizations are limited (a) to the use of the person or entity reporting to CCC and (b) to the use of a specific customer 
of the person or entity reporting to CCC unless otherwise indicated in the permissions policy statement printed in the 
publication. Other limitations may be imposed by individual publications, as described in their own masthead or permission 
policy statements.
3. Uses expressly excluded: 
electronic storage of any reproduction (whether in plain-text, PDF, or any other format) other than on a transitory 
basis 
•
the input of works into computerized databases •
reproduction of an entire publication (cover-to-cover) •
reproduction for resale to anyone other than a specific customer •
republication in a different form•
Please obtain authorizations for these uses through other CCC services or directly from the rightsholder.
All rights not expressly granted are reserved; any license granted is further limited as set forth in any restrictions included 
in the Order Confirmation and/or in these terms and conditions.
4. Copyright Rights.
All Works and all rights therein, including copyright rights, remain the sole and exclusive property of the Rightsholder. The 
license created by the exchange of an Order Confirmation (and/or any invoice) and payment by User of the full amount set 
forth on that document includes only those rights expressly set forth in the Order Confirmation and in these terms and 
conditions, and conveys no other rights in the Work(s) to User.
5. Payment and Term.
While User may exercise the rights licensed immediately upon issuance of the Order Confirmation, the license is 
automatically revoked and is null and void, as if it had never been issued, if complete payment for the license is not 
received on a timely basis either from User directly or through a payment agent, such as a credit card company. In the 
event that the material for which an electronic reproduction license is sought includes third party materials (such as 
photographs, illustrations, graphs and similar materials) which are identified as included in a Work by permission, such 
third party materials may not be reproduced except in the context of the Work. Unless otherwise provided in the Order 
Confirmation, any grant of rights to User (i) is "one-time", (ii) is non-exclusive and non-transferable, and (iii) is limited to 
one year all as measured from the "republication date" as identified in the Order Confirmation, if any, and otherwise from 
the date of the Order Confirmation. Upon completion of the licensed use, or at the end of the period identified in the 
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previous sentence (if earlier), User shall immediately cease any new use of the Work(s) and shall destroy any further 
copies of the Work (except for copies printed on paper in accordance with this license and still in User's stock at the end of 
such period).
6. Limitations on Use.
User may not make or permit any alterations to the Work, unless expressly set forth in the Order Confirmation (after 
request by User and approval by Rightsholder). No Work may be used in any way that is defamatory, violates the rights of 
third parties (including such third parties' rights of copyright, privacy, publicity, or other tangible or intangible property), 
or is otherwise illegal, sexually explicit or obscene. In addition, User may not conjoin a Work with any other material that 
may result in damage to the reputation of the Rightsholder.
7. Duty to Inform.
User agrees to inform CCC if it becomes aware of any infringement of any rights in a Work and to cooperate with any 
reasonable request of CCC or the Rightsholder in connection therewith.
8. Indemnification.
User hereby indemnifies and agrees to defend the Rightsholder and CCC, and their respective employees and directors, 
against all claims, liability, damages, costs and expenses, including legal fees and expenses, arising out of any use of a 
Work beyond the scope of the rights granted herein, or any use of a Work which has been altered in any way by User, 
including claims of defamation or infringement of rights of copyright, publicity, privacy or other tangible or intangible 
property.
9. LIMITATION OF LIABILITY.
(a) UNDER NO CIRCUMSTANCES WILL CCC OR THE RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, 
CONSEQUENTIAL OR INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR LOSS OF BUSINESS 
PROFITS OR INFORMATION, OR FOR BUSINESS INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A 
WORK, EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
(b) IN ANY EVENT, THE TOTAL LIABILITY OF THE RIGHTSHOLDER AND CCC (INCLUDING THEIR RESPECTIVE EMPLOYEES 
AND DIRECTORS) SHALL NOT EXCEED THE TOTAL AMOUNT ACTUALLY PAID BY USER FOR THIS LICENSE. USER ASSUMES 
FULL LIABILITY FOR THE ACTIONS AND OMISSIONS OF ITS PRINCIPALS, EMPLOYEES, AGENTS, AFFILIATES, 
SUCCESSORS AND ASSIGNS.
10. WARRANTIES; DISCLAIMERS.
(a) THE WORK(S) AND RIGHT(S) ARE PROVIDED "AS IS". THE RIGHTSHOLDER(S) HAS GRANTED CCC THE RIGHT TO 
GRANT PERMISSION UNDER THESE PAY-PER-USE SERVICES, AND HAS WARRANTED THAT IT HAS ALL RIGHTS 
NECESSARY TO AUTHORIZE CCC TO ACT ON ITS BEHALF. CCC AND THE RIGHTSHOLDER DISCLAIM ALL OTHER 
WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT 
LIMITATION IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. ADDITIONAL 
RIGHTS MAY BE REQUIRED TO USE PORTIONS OF THE WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER 
CONTEMPLATED BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE RIGHTSHOLDER MAY HAVE 
SUCH ADDITIONAL RIGHTS TO GRANT.
(b) USER ACKNOWLEDGES THAT THE RIGHTS GRANTED HEREUNDER OR UNDER ANY ORDER CONFIRMATION DO NOT 
INCLUDE ANY MODEL, PROPERTY OR OTHER RELEASES WHICH MAY BE NECESSARY FOR CERTAIN USES OF WORKS 
CONSISTING OF OR CONTAINING PHOTOGRAPHS, OTHER STILL IMAGES OR AUDIOVISUAL CONTENT. USER 
ACKNOWLEDGES THAT ADDITIONAL RIGHTS OR RELEASES MAY BE NECESSARY FOR CERTAIN USES OF MATERIALS 
WHICH INCLUDE DEPICTIONS OF PERSONS, PROPERTY OR TRADEMARKS AND THAT USER (AND NOT CCC OR ANY 
RIGHTSHOLDER) IS SOLELY RESPONSIBLE FOR OBTAINING ANY SUCH REQUIRED RIGHT OR RELEASE.
11. Miscellaneous
11.1: Assignment or Transfer: The licensing transaction described in the Order Confirmation is personal to User. Therefore, 
User may not assign or transfer to any other person (whether a natural person or an organization of any kind) the license 
created by the Order Confirmation and these terms and conditions or any rights granted hereunder, subject to the 
following exception. The exception: in cases where a person is specifically engaged by a second person to provide 
reproductions of Works to (and/or to obtain licenses on behalf of) the second person and EITHER (i) the first person 
expressly notifies the second person of its obligation not to redistribute or otherwise use the material without 
authorization, OR (ii) the second person is identified in the Order Confirmation as the publisher of the material to include 
the Work licensed under this service, then the license may be transferred to the second person and both the first person 
and the second person shall be jointly deemed to be the "User" under the Order Confirmation and these terms and 
conditions for that transaction. An organizational User and its principals, employees, agents and affiliates are jointly and 
severally liable for the performance of all payments and other obligations hereunder.
11.2: Amendment or Waiver, Objection to Contrary Terms. No amendment or waiver of any terms is binding unless set 
forth in a writing other than a standard User or CCC form and signed by the parties. The Rightsholder and CCC hereby 
object to any terms contained in any writing prepared by the User or its principals, employees, agents or affiliates and 
purporting to govern or otherwise relate to the licensing transaction described in the Order Confirmation, which terms are 
in any way inconsistent with any terms set forth in the Order Confirmation and/or in these terms and conditions or CCC's 
standard operating procedures, whether such writing is prepared prior to, simultaneously with or subsequent to the Order 
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a separate instrument.
11.3: Effect of Breach. Any failure by User to pay any amount when due, or any use by User of a Work beyond the scope 
of the license set forth in the Order Confirmation and/or these terms and conditions, shall be a material breach of the 
license created by the Order Confirmation and these terms and conditions. Any breach not cured within 10 days of notice 
thereof shall result in immediate termination of such license without further notice. Invoices are due and payable upon 
receipt. Any unauthorized (but licensable) use of a Work that is terminated immediately upon notice thereof may be 
liquidated by payment of the Rightsholder's ordinary license price therefore; any unauthorized (and unlicensable) use that 
is not terminated immediately for any reason (including, for example, because materials containing the Work cannot 
reasonably be recalled) will be subject to all remedies available at law or in equity, but in no event to a payment of less 
than three times the Rightsholder's ordinary license price for the most closely analogous licensable use plus Rightsholder's 
and/or CCC's costs and expenses incurred in collecting such payment.
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11.4: Governing Law and Jurisdiction. The licensing transaction described in the Order Confirmation document shall be 
governed by and construed under the law of the State of New York, USA, without regard to the principles thereof of 
conflicts of law. Any case, controversy, suit, action, or proceeding arising out of, in connection with, or related to such 
licensing transaction shall be brought, at CCC's sole discretion, in any federal or state court located in the County of New 
York, State of New York, USA, or in any federal or state court whose geographical jurisdiction covers the location of the 
Rightsholder set forth in the Order Confirmation. The parties expressly submit to the personal jurisdiction and venue of 
each such federal or state court.
If you have any comments or questions about this pay-per-use service or Copyright Clearance Center, please contact us at 
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